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Haploinsufficiency for alpha- and gamma-adaptin binding protein (AAGAB) p34 causes clin-
ically heterogeneous forms of punctate palmoplantar keratoderma
E Pohler,1 O Mamai,2 J Hirst,3 M Zamiri,4 H Horn,5 AD Irvine,6 T Nomura,7 JA McGrath,8
CA Munro4 and W McLean1 1 Dermatology and Genetic Medicine, University of Dundee,
Dundee, United Kingdom, 2 Farhat Hached University Hospital, Sousse, Tunisia, 3 Cambridge
Institute for Medical Research, Cambridge, United Kingdom, 4 Southern General Hospital,
Glasgow, United Kingdom, 5 Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, 6
Our Lady’s Children’s Hospital, Dublin, Ireland, 7 University of Hokkaido, Sapporo, Japan and
8 King’s College London, London, United Kingdom
Punctate palmoplantar keratodermas (PPPKs) are characterized by circumscribed hyperkeratotic
lesions on palms and soles. These genodermatoses exhibit both clinical and genetic heterogeneity.
By applying whole exome sequencing to a Scottish kindred with autosomal dominant PPPK (OMIM
#148600), we identified a heterozygous heterozygous nonsense mutation in AAGAB, encoding
alpha- and gamma-adaptin binding protein p34. This gene is located within a previously reported
PPPK locus on chromosome 15q22. Conventional sequencing identified a further 7 heterozygous
loss-of-function mutations in 17 additional families with severe or mild forms of PPPK. The p34
polypeptide has a GTPase domain related to the Rab superfamily of vesicle transport proteins and
was shown biochemically to bind both alpha- and gamma-adaptins, indicative of a role in vesicle
biology. Ultrastuctural analysis of lesional epidermis confirmed abnormalities of intracellular vesi-
cle populations. Immunohistochemistry showed hyperproliferative basal cells within the punctate
lesions. RNAi knockdown of p34 in keratinocytes led to increased cell division and a marked increase
in epidermal growth factor receptor (EGFR) protein, as well as alterations in the abundance and/or
phosphorylation of a number of downstream signaling molecules. We hypothesize that p34 defi-
ciency impairs endocytic recycling of EGFR, leading to a hyperproliferative form of hyperkeratosis
due to increased EGFR signaling.
502 
Impaired epithelial differentiation of induced pluripotent stem cells from EEC ectodermal
dysplasia patients is rescued by a small compound APR-246/PRIMA-1MET
R Shalom-Feuerstein,1 I Petit,2 L Serror,2 E Aberdam,1 H Zhou,3 H van Bokhoven,3 K Wiman4 and
D Aberdam1 1 INSERM U633, Evry, France, 2 INSERTECH, Haifa, Israel, 3 Radboud University
Nijmegen Medical Centrum,, Nijmegen, Netherlands and 4 Karolinska Institutet, Stockholm,
Sweden
Ectodermal dysplasia is a group of congenital syndromes affecting a variety of ectodermal deriva-
tives. Among them, ectrodactyly, ectodermal dysplasia and cleft lip/palate (EEC) syndrome is caused
by single point mutations in the p63 gene, which controls epidermal development and homeosta-
sis. Phenotypic defects of the EEC syndrome include skin defects and limbal stem cell deficiency.
In this study, we designed a novel cellular model that recapitulated major embryonic defects related
to EEC. Fibroblasts from healthy donors and EEC patients carrying two different point mutations in
the DNA binding domain of p63 were reprogrammed into induced pluripotent stem cell (iPSC) lines.
EEC-iPSC from both patients showed early ectodermal commitment into K18+ progenitor cells but
failed to further properly differentiate into K14+ cells (epidermis/limbus) or K3/K12+ cells (corneal
epithelium). APR-246 (PRIMA-1MET), a small compound that restores functionality of mutant p53
in human tumor cells, could revert corneal epithelial lineage commitment and reinstate normal p63-
related signaling pathway. This study illustrates the relevance of iPSC for p63-related disorders. This
unique model serves to characterize the abnormal molecular circuitry of this congenital disease and
paves the way for future therapy of EEC.
504
p63 Transcription Factor Controls Expression of the Nuclear Envelope Components and Organ-
ization of the Nuclear Architecture During Development of the Epidermis
V Rapisarda,1 AN Mardaryev,1 MR Gdula,2 AA Sharov,2 MY Fessing,1 I Karakesisoglou,3
CJ Hutchinson3 and VA Botchkarev1 1 Centre for Skin Sciences, University of Bradford,
Bradford, United Kingdom, 2 Department of Dermatology, Boston University, Boston, MA and
3 School of Biological Sciences, University of Durham, Durham, United Kingdom
During development, multipotent progenitor cells establish tissue-specific programmes of gene
expression that underlie a process of differentiation into specialized cell types. p63 transcription
factor plays an important role in the control of establishing distinct three-dimensional conforma-
tions in the Epidermal Differentiation Complex (EDC) locus in epidermal keratinocytes via con-
trolling the expression of the genome organizer Satb1. Here we show that during epidermal mor-
phogenesis in mice, p63 also regulates the proper balance of expression of nuclear
envelope-associated proteins. In p63-null epidermis, about 20% of nuclei showed misshapen lob-
ulated morphology. Alterations of the nuclear shape in p63-null mice were accompanied by decreased
expression of nuclear Lamins (A/C, B1) components of the LINC complex (Sun-1, Nesprin-2/3) and
Plectin, compared to WT controls. Furthermore, p63 showed binding to the promoter region of
Plec 1c gene, encoding Plectin 1c isoform that links nesprin-3 with the cytokeratin intermediate fil-
aments. Alterations of the nuclear shape in keratinocytes of p63-null mice were accompanied by
defects in the distribution of the peripherial heterochromatin associated modifications with decreased
expression of the heterochromatin protein 1α and repressive histone marker H3K27me3, as well as
by the re-distribution of the heterochromatin protein 1γ and H3K9me3 in the nucleus. These data
demonstrate that p63-regulated gene expression programme in keratinocytes includes not only genes
encoding adhesion molecules, cytoskeleton proteins and chromatin remodelling factors, but also
distinct components of the nuclear envelope, thus suggesting the existence of the functional links
between cytoskeleton, nuclear architecture and three-dimensional nuclear organization.
503 
Topical enzyme replacement therapy restores transglutaminase 1 activity and corrects archi-
tecture of transglutaminase 1 deficient skin grafts
K Aufenvenne,1 F Larcher,2 I Hausser,3 M Del Rio,2 M Dathe4 and H Traupe1 1 Dept of
Dermatology, University Hospital, Münster, Germany, 2 Epithelial Biomedicine Division,
CIEMAT, Madrid, Spain, 3 Dept of Dermatology, University Hospital, Heidelberg, Germany
and 4 Leibniz Institute of Molecular Pharmacology, Berlin, Germany
Transglutaminase 1 deficient lamellar ichthyosis (LI) is a severe genetic skin disease, caused by muta-
tions in TGM1. TGM1 encodes transglutaminase 1 (TG1), an intracellular key enzyme for forma-
tion of the cornified envelope. TG1 deficiency is characterized by collodion baby at birth, dramat-
ically increased transepidermal water loss and lifelong pronounced scaling of the skin. In addition
to clinical investigations and sequencing of TGM1, in situ monitoring of TG1 activity and ultra-
structural analysis showing cholesterol clefts as important markers further confirm the diagnosis.
Currently no causative therapy is available. A variety of methods only provide symptomatic relief.
In this study we intended to develop a therapy, which overcomes the problems of insufficient mem-
brane penetration of drugs and low target specificity. Liposomes have been studied as a promising
drug delivery model and are able to deliver bioactive compounds into different cells. We devel-
oped sophisticated liposomes with encapsulated recombinant human TG1, which were coupled
with a specialized peptide to mediate cellular uptake. These liposomes provided sustained deliv-
ery of TG1 into primary keratinocytes. To show the general feasibility of this approach we used a
skin-humanized mouse model for TG1 deficiency which allows us to test the TG1-liposomes in a
humanized context. After treatment we observed a considerable improvement of the ichthyosis phe-
notype. Treatment with TG1-liposomes, in contrast to empty liposomes, resulted in normalization
of the regenerated LI skin: in situ monitoring in frozen sections showed a restoration of TG1 activ-
ity and ultrastructurally cholesterol clefts were no longer detectable. We conclude that this topical
approach is a promising strategy to restore epidermal integrity and barrier function in individuals
with LI due to transglutaminase 1 deficiency.
501
Integrin α3 Mutations cause a new disease affecting kidney, lung and skin
C Has,1 D Kiritsi,1 Y He,1 G Sparta,2 I Hausser,3 D Bockenhauer,4 B Deckel,5 F Hildebrandt,6
GF Laube2 and L Bruckner-Tuderman1 1 Dermatology, University of Freiburg, Freiburg,
Germany, 2 Paediatric Nephrology, Children’s Hospital, Zürich, Switzerland, 3 Dermatology,
University of Heidelberg, Heidelberg, Germany, 4 GOS Hospital for Children, London, United
Kingdom, 5 Paediatric Nephrology, Sheba medical Center, Tel Aviv, Israel and 6 Paediatrics,
University of Michigan, Ann Arbor, MI
Integrin Integrin α3 is a transmembrane integrin receptor subunit that mediates signals between the
cells and their microenvironment. In mouse models, loss of integrin α3 caused skin fragility asso-
ciated with abnormal kidney and lung organogenesis. Here, we identified three patients with homozy-
gous mutations in the integrin α3 gene, which were associated with disrupted basement membrane
structures and compromised barrier functions in kidney, lung and skin. The patients had a multi-
organ disorder that included congenital nephrotic syndrome, interstitial lung disease and epider-
molysis bullosa. The renal and respiratory features predominated, and the lung involvement deter-
mined the lethal course of the disease. Although skin fragility was mild, it provided clues to the
diagnosis. Integrin α3-negative human skin was atrophic and exhibited detachment of basal ker-
atinocytes from the basement membrane. Transmission electron microscopy and immunofluores-
cence staining revealed abnormalities of the dermal-epidermal junction, with a thin and discon-
tinuous lamina densa between the hemidesmosomes. In contrast, intercellular adhesions and
epidermal proliferation were not affected. Although integrin α3-null keratinocytes were devoid of
this integrin on the cell surface, they spread well on laminin 332 in vitro. This partial rescue was
integrin α6-dependent, as shown by cell spreading assays using blocking antibodies. Deficiency of
integrin α3 increased random migration of keratinocytes and enhanced expression of laminin 332
and fibronectin. Taken together, we idenfied a new human multi-organ disease and used integrin
α3-null skin and keratinocytes to demonstrate that the molecular disease mechanisms relate to per-
turbed epithelial-mesenchymal interactions.
505 
Revertant mosaicism in Kindler syndrome results from slipped mispairing and mitotic recom-
bination
D Kiritsi,1 Y He,1 AM Pasmooij,2 M Onder,3 R Happle,1 M Jonkman,2 L Bruckner-Tuderman1 and
C Has1 1 Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany,
2 Department of Dermatology, University Medical Center Groningen, Groningen,
Netherlands and 3 Department of Dermatology, Gazi University Faculty of Medicine, Ankara,
Turkey
Spontaneous gene repair, also called revertant mosaicism, has been documented in several genetic
disorders involving organs that undergo self-regeneration, including the skin. Here, we describe a
disseminated pattern of revertant mosaicism observed in six patients with Kindler syndrome, a gen-
odermatosis caused by loss of kindlin-1 and clinically characterized by skin blistering and pro-
gressive poikiloderma. All patients exhibited numerous normal-appearing skin patches on the back-
ground marked by atrophy and dyspigmentation, and presented germline duplication mutations
(c.456dupA and c.676dupC) in the kindlin-1 gene. Using laser dissection microscopy to isolate
DNA from the reverted epidermal areas, we identified slipped mispairing in direct nucleotide repeats
as the repair mechanism in all investigated revertant skin spots. The sequence around the mutations
demonstrated high propensity to mutations, favoring both microinsertions and –deletions. Addi-
tionally, in some revertant patches mitotic recombination generated areas with homozygous nor-
mal keratinocytes. Restoration of kindlin-1 expression led, not only to clinically, but also structurally
(i.e. epidermal thickness, proliferation, dermal-epidermal junction) normal skin. Since loss of kindlin-
1 severely impairs keratinocyte proliferation, we predict that revertant cells have a selective advan-
tage that allows their clonal expansion and, consequently, the improvement of the skin condition.
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Activators of the ectodysplasin pathway are redefining the timing and opportunities for mod-
ulation of ectoderm development
K Huttner,1 M Casal,2 O Gaide,3 C Kowalczyk,4 D Headon5 and P Schneider4 1 Edimer
Pharmaceuticals, Inc., Cambridge, MA, 2 School of Veterinary Medicine, University of
Pennsylvania, Philadelphia, PA, 3 Geneva University, Geneva, Switzerland, 4 Dept of
Biochemistry, University of Lausanne, Epalinges, Switzerland and 5 The Roslin Institute,
University of Edinburgh, Midlothian, United Kingdom
Ectodysplasin A1 (EDA-A1) is a protein modulator of ectoderm development, playing an integral
role in the initiation and maturation of ectodermal appendages. EDA-A1 deficiency results in the
genetic disorder X-linked hypohidrotic ectodermal dysplasia (XLHED), characterized by hypohidrosis,
hypodontia, hypotrichosis and serous gland hypoplasia. Both a recombinant EDA-A1 protein (EDI200)
and an agonist EDA-A1 receptor monoclonal antibody (mAbEDAR1) are capable of correcting key
features of XLHED in mice and dogs following parenteral dosing and possibly through breast milk
passage. Using these molecular tools, studies to define windows of efficacy were conducted in
both animal models. In XLHED mice, EDI200 exposure in sequential 24 hour periods of embryonic
development identified unique and in many cases non-overlapping timeframes for appendage acti-
vation at specific anatomic locations. In analogous studies involving neonatal XLHED dogs, vary-
ing the EDI200 dose regimen and day of initiation mapped a time course for dental and functional
respiratory tract development. While short course therapy in XLHED mouse pups was associated
with rapid activation of the EDA-A1/EDAR pathway and correction of ectodermal structures, weekly
dosing of mature XLHED mice with mAbEDAR1 over a period of months also demonstrated a sig-
nificant correction of glandular hypoplasia. This unexpected result suggests a developmental plas-
ticity with therapeutic implications beyond the neonatal period. Finally, EDA-A1/EDAR activation
in wild-type mice modulated both hair follicle and glandular development, supporting the hypoth-
esis that enhanced expression of the ectodysplasin pathway may prove useful in the clinic outside
the setting of genetic disorders.
507
A Truncating Germline Mutation In The Gene Encoding Folliculin-Interacting Protein FNIP1
Is Associated With Familial Multiple Discoid Fibromas, A Look-Alike Of Birt-Hogg-Dubé
Syndrome
T Claessens,1 M van Steensel,1 T Starink,2 Q Waisfisz3 and F Menko3 1 Dermatology, Maastricht
University Medical Center, Maastricht, Netherlands, 2 Dermatology, VU Medical Center,
Amsterdam, Netherlands and 3 Clinical Genetics, VU Medical Center, Amsterdam,
Netherlands
Recently, we delineated familial multiple discoid fibromas (FMDF), an autosomal dominant con-
dition with skin features resembling fibrofolliculomas. We excluded involvement of the FLCN
locus associated with Birt-Hogg-Dubé syndrome (BHD). Here we report the genetic background of
FMDF. FMDF was previously described in nine families. Based on the putative involvement of fol-
liculin interacting proteins FNIP1 and FNIP2 in BHD, we performed segregation analysis in two kin-
dreds using closely linked STR markers of both genes and DNA sequence analysis in seven kin-
dreds aimed at the possible association of these candidate genes with FMDT. Segregation analysis
showed that the inheritance of the FNIP1 locus was compatible with linkage while FNIP2 was
excluded. In seven families, sequence analysis revealed a heterozygous germline mutation c.1989delT
which predicts the frameshift p.Val663fsX6. Haplotype analysis and genealogical studies demon-
strated common ancestry for six of these kindreds.Familial multiple discoid fibromas is associated
with a FNIP1 germline mutation. Ongoing studies are aimed at the molecular pathogenesis of FMDF.
508 
A Genetic and Functional Link Between iRhom2 and ADAM17 in Tylosis with Oesophageal
Cancer
MA Brooke, SL Etheridge, DC Blaydon and DP Kelsell Centre for Cutaneous Research, Blizard
Insitute, QMUL, London, United Kingdom
We recently linked the autosomal dominant inherited disorder Tylosis with Oesophageal Cancer
(TOC) to mutations in the inactive rhomboid protein iRhom2. TOC is a condition of palmoplantar
keratoderma with a vastly increased lifetime risk of oesophageal cancer. iRhom2’s functions are
relatively poorly understood, but include regulation of the Epithelial Growth Factor (EGF) sig-
nalling pathway. Previously, we have shown increased activation of the EGF signalling pathway in
TOC keratinocyte cell lines, and that TOC keratinocytes migrate significantly faster than controls
during scratch wound assays, particularly in the absence of exogenous EGF. This led us to investi-
gate the role of ADAM17 (TACE), an ectodomain sheddase enzyme largely responsible for prote-
olytic release of EGF-family ligands. We have previously linked ADAM17 loss of function muta-
tions with neonatal onset skin and bowel inflammation, associated with severely abrogated secretion
of ADAM17 substrates. Western blotting of ADAM17 in TOC keratinocytes demonstrated an increased
ratio of mature ADAM17 to pre-ADAM17, and elevated levels of the free ADAM17 pro-domain
(removed during ADAM17 maturation) compared to controls, indicating increased ADAM17 pro-
cessing. Furthermore, immunocytochemistry demonstrated greater localisation of ADAM17 to the
plasma membrane (its primary site of activity) in TOC cells alongside a significant presence in the
Golgi apparatus. Stimulation of TOC keratinocytes and tylosis-patient-derived PBMCs with LPS or
PMA revealed greatly increased production of ADAM17 substrates compared to controls, includ-
ing the pro-inflammatory cytokines TNFα, IL-6 and IL-8, and the growth factor Amphiregulin. Impor-
tantly, siRNA knockdown of ADAM17 abolished this increase, indicating this excessive secretory
phenotype is ADAM17-dependent. The increased processing and activity of ADAM17 seen in TOC
keratinocytes suggest that TOC-associated mutations in iRhom2 are gain of function in nature, thus
contributing to the TOC phenotype via upregulation of ADAM17 and therefore EGF signalling.
509 
Porokeratotic eccrine nevus may be caused by somatic connexin26 mutations
J Easton,1 P Martin2 and M van Steensel1 1 Dermatology, Maastricht University Medical Center,
Maastricht, Netherlands and 2 Department of Life Sciences, School of Health and Life
Sciences, Glasgow, United Kingdom
Porokeratotic eccrine ostial and dermal duct nevus, or porokeratotic eccrine nevus (PEN), is a hyper-
keratotic epidermal nevus. Several cases of widespread involvement have been reported, including
one in association with keratitis-ichthyosis-deafness syndrome (KID, MIM #148210), a rare disor-
der caused by mutations in the GJB2 gene coding for the gap junction protein connexin26 (Cx26).
The molecular cause is, as yet, unknown. We have noted that PEN histopathology is shared by KID.
The clinical appearance of PEN can resemble that of KID syndrome. Furthermore, a recent report
of cutaneous mosaicism for a GJB2 mutation associated with KID describes linear hyperkeratotic
skin lesions that might be consistent with PEN. From this, we hypothesised that PEN might be caused
by Cx26 mutations associated with KID or similar gap junction disorders. Thus, we analysed the
GJB2 gene in skin samples from two patients referred with generalised PEN. In both we found GJB2
mutations in the PEN lesions, but not in unaffected skin or peripheral blood. One mutation was
already known to cause KID syndrome, the other had not been previously associated with skin symp-
toms. We provide extensive functional data to support its pathogenicity. We conclude that PEN
may be caused by mosaic GJB2 mutations.
510 
Role of dermal microeenvironment in basal cell carcinoma susceptibility of Nevoid Basal Cell
Carcinoma / Gorlin’ syndrome
E Burty,1 Y Gache,1 G Gendronneau,1 F Brellier,1 A Valin,1 S Scarzello,1 M Avril2 and T Magnaldo1
1 CNRS UMR6267 – INSERM U998, Nice, France and 2 Dermatology Department, Service
de Dermatologie, Université Paris 5-APHP, Paris,, Paris, France
Basal cell carcinoma (BCC) is the commonest tumor in human. About 70 % sporadic BCCs bear
somatic mutation in the PATCHED tumor suppressor gene which encodes the receptor for the
Sonic Hedgehog morphogen. PATCHED germinal mutations are associated with the dominant Nevoid
Basal Cell Carcinoma Syndrome (NBCCS), a major hallmark of which is a high susceptibility to
BCCs. Although sporadic BCCs arise almost excusively in sun exposed skin area, 40 to 50 % BCC
from NBCCS patients develop in non photo exposed skin areas. Overwelming evidences indicate
that microenvironment may be both modified by- and influence the- epithelial tumor. We hypoth-
esized that NBCCS fibroblasts could contribute to BCC in NBCCS patients, notably in non photo
exposed skin area. Primary NBCCS fibroblasts in dermal equivalents expressed a 18 mRNA signa-
ture close to that of fibroblasts associated to sporadic BCCs including MMP1 and 3, CXCL12,
FGF7, TNC, ANGPTL4, but no member of the SHH pathway. The functional impact of NBCCS fibrob-
lasts was assessed in organotypic skin cultures with control keratinocytes. Onset of epidermal dif-
ferentiation was delayed. Keratinocyte proliferation was severely reduced and showed high levels
of nuclear P53. Cyclin B1, a direct transcriptional target of P53 known to interact with PATCHED,
was strickingly reduced. Culture of control keratinocytes in media conditioned by NBCCS fibrob-
lasts resulted in a significant drop of Cyclin B1. These data suggest that a subset of factors secreted
by NBCCS fibroblasts generate a stress affecting keratinocytes that strongly impact epidermal home-
ostasis. Altered dermo/epidermal interactions could contribute to BCC susceptibility in NBCCS.
511
Skin fragility is associated with reduced desmosome formation in AEC syndrome
G Ferone,1 HA Thomason,2 L De Rosa,1 H Zhou,3 H van Bokhoven,3 J Dixon2 and C Missero1 1
CEINGE - Center for Genetic Engineering, Napoli, Italy, 2 University of Manchester,
Manchester, United Kingdom and 3 Radboud University, Nijmegen, Netherlands
p63 is a master regulator of epidermal gene expression and is required for epidermal morphogen-
esis. Missense mutations in the p63 gene are causative of some related ectodermal dysplasia and
cleft palate syndromes. In contrast to other p63-associated disorders, AEC syndrome (OMIM 106260)
is characterized by severe skin anomalies, particularly in neonates and infants, including congen-
ital erythroderma, skin fragility, and erosions most prominently on the scalp. However, standard
treatment for such severe skin symptoms only involves gentle wound care to prevent infections. To
dissect the molecular mechanisms underlying these alterations, we used a knock-in mouse model
for AEC syndrome carrying a phenylalanine substitution in position 514 (L514F), a mutation causative
of AEC syndrome. p63+/L514F heterozygous mice display hypoplastic and fragile skin, ectodermal
dysplasia and cleft palate, thus closely resembling the defects observed in individuals affected by
AEC syndrome. Histologically, we detected intra-epidermal blisters between the basal and suprabasal
cell layers in a significant fraction of mutant mice. Ultrastructural evaluation of cell-cell contacts
obtained by electron microscopy indicated a reduction of desmosomes in p63+/L514F epidermis.
Desmosomes had a loose appearance or were frankly split in half, although occasionally they were
associated entirely with only one of the two cells. These contacts were primarily reduced between
the basal and suprabasal cells and to a lesser extent between suprabasal cells, in line with the
localization of blistering. Several desmosomal genes were directly regulated by p63, and a specific
subset was reduced in AEC mutant epidermis and in primary mutant keratinocytes. Interestingly,
defects in mechanical resistance in mutant keratinocytes were specifically alleviated by EGFR
inhibitors that are known to stabilize desmosome assembly.
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HDAC inhibition prevents loss of subcutaneous fat in CSB-deficient mice
M Majora, C Goetz, C Schumacher, M Schneider, I Uthe and J Krutmann IUF-Leibniz Research
Institute for Environmental Medicine, Duesseldorf, Germany
Cockayne syndrome (CS) is a progeroid disease caused by mutations in either the CSB or CSA gene.
Cells lacking a functional CSB protein are characterized by compromised DNA repair and inabil-
ity to mount normal transcriptional responses towards UV radiation. We have previously shown that
CSB-deficient hairless mice are resistant against wrinkle formation upon chronic UVA irradiation
but similar to CS patients are prone to loss of subcutaneous fat. These findings correlated with
decreased expression of the major murine collagenase MMP-13 and increased expression of the
anti-adipogenic enzyme MMP-3 in the skin of UVA-irradiated CSB-deficient mice in comparison
to wildtype mice. According to that, a single dose UVA irradiation of CSB-deficient and wildtype
MEFs resulted in a similar phenotype with regard to the differential expression of MMP-13 and MMP-
3. We now report that the UVA-induced aberrant gene expression profile in CSB-deficient MEFs was
accompanied by an increased expression and phosphorylation of c-Jun, a factor which is known to
be involved in transcriptional regulation of various MMP genes. Interestingly, treatment with the his-
tone deacetylase (HDAC) inhibitor SAHA could restore the abnormal expression levels of MMP-13
and MMP-3 in CSB-deficient cells to wildtype levels upon UVA irradiation. While low levels of
SAHA tend to stimulate expression of MMP-13 and MMP-3 in both CSB-deficient and wildtype
MEFs high doses inhibit induction of both genes. In parallel, low levels of SAHA enhance expres-
sion and phosphorylation of c-Jun while high doses block c-Jun accumulation. Even more impor-
tant, oral administration of SAHA significantly reduced spontaneous as well as UVA radiation-
induced loss of subcutaneous fat in vivo in CSB-deficient mice. These data indicate that the defective
transcriptional response towards UVA radiation in CSB-deficient cells can be normalized by HDAC
inhibitors at least for some genes. Moreover, they suggest that aberrant protein acetylation may be
a novel molecular mechanism contributing to the pathology of CS.
514
Intradermal injection of recombinant human type VII collagen restores collagen function in
a canine model of dystrophic epidermolysis bullosa
D Pin,1 D Woodley,2 E Vidémont,1 M Amir,2 B Hwang,2 M de Souza,4 D Keene3 and M Chen2 1
Dermatology ICE research Unit, VetAgro Sup Campus Vétérinaire, Marcy L’Etoile, France, 2
Dermatology, University of Southern California, Los Angeles, CA, 3 Dermatology, Shriners
Hospital for Children, Portland, OR and 4 Lotus Tissue Repair, Inc, Cambridge, MA
In this study, we used a canine spontaneous REBD model which recapitulates the main features of
human recessive dystrophic epidermolysis bullosa. We injected rhC7, purified from culture medium
of gene-corrected RDEB fibroblast, intradermally into sites situated around lesions on the lips and
ears on one side of the body. PBS with 0.5 mM EDTA was used as control and injected into similar
sites on the other side of the body. A clinical follow-up was done and skin biopsies, taken from var-
ious times after injection from sites on both sides, were subjected to immunostaining and immu-
noelectron microscopy labeling with a monoclonal antibody specific for human C7 and that does
not cross react with dog C7. Clinically, the injected sites were less inflamed, less erythematous, and
presented no erosions after C7 injection when compared with either sites before injection or un-
injected control sites. One week after intradermal injection, the injected rhC7 was transported
from the dermis, incorporated into the DEB dog’s BMZ and corrected dermal-epidermal separation.
The BMZ localization of the injected rhC7 was confirmed by co-labeling the same sections of dog
skin with a polyclonal antibody that recognizes both canine and human C7. Immunoelectron
microscopy showed that the injected human rhC7 incorporated into the dog’s BMZ and formed
human AFs. This study in a spontaneous large animal model shows that intradermally injected human
C7 can readily incorporate into the BMZ and restores C7 function. Since RDEB dogs have a mis-
sense mutation and express endogenous mutated protein, one important implication is that injected
hC7 can incorporate into the BMZ that already have mutated C7 as it is the case in a large number
of human RDEB patients.
516
Identification of MCP-1 as a key effector of IL-31 signaling in Primary Cutaneous Amyloido-
sis
Y Shiao,1 H Chung,1 K Chiang,1 Y Chang,2 D Lee,2 C Chen,2 M Lin,3 S Tsai1 and I Matsuura1 1
National Health Research Institutes, Zhunan, Taiwan, 2 Taipei Veterans General Hospital,
Taipei, Taiwan and 3 National Yang-Ming University, Taipei, Taiwan
Primary cutaneous amyloidosis (PCA) is an itchy skin disorder that is relatively common in South
America and Southeast Asia. We recently identified missense mutations from patients with familial
PCA (FPCA) in either of the two subunits of the receptor for interleukin-31 (IL-31). To investigate the
significance of the disease-derived mutation, we reconstituted in HaCaT human keratinocyte cell
line a functional IL-31 receptor by exogenously expressing IL-31RA or an FPCA-derived mutant, IL-
31RAS521F. Monocyte chemotactic protein-1 (MCP-1) was induced in the wild-type cells with IL-
31 stimulation. This induction, however, was abrogated in mutant cells. MCP-1 is a secreted
chemokine that can recruit innate immune cells to keratinocytes to scavenge cellular debris. In
chemotaxis assay, monocytes were attracted to conditioned medium from IL-31-treated wild-type
cells but not to that from the mutant cells. MCP-1 is the major chemoattractant in the conditioned
medium as the chemoattraction ability is neutralized by MCP-1 antibody. In agreement with these
in vitro observations, immunostaining of PCA skin samples showed much reduced level of MCP-1
compared to other skin condition samples. At the molecular level, the FPCA mutation attenuates
STAT3 activation. STAT3 is an important factor to regulate MCP-1 expression as STAT3 knockdown
by siRNA attenuated its expression. Thus, the diminished MCP-1 expression with the IL-31RA mutant
is attributed, at least in part, to the reduced STAT3 activation. Taken together, our study suggests defi-
ciency of immune cell chemoattraction by keratinocytes due to compromised MCP-1 production
resulted from the IL-31RA mutation may play a role in FPCA pathogenesis.
515 
Mutations in the ABCC6 Gene Can Cause Generalized Arterial Calcification of Infancy in
Addition to Pseudoxanthoma Elasticum
Q Li,1 JL Brodsky,2 L Conlin,2 J Bradfield,2 B Pawel,2 A Glatz,2 LJ Schurgers,3 MA Deardoff,2
M Levine2 and J Uitto1 1 Dermatology and Cutaneous Biology, Jefferson Medical College,
Philadelphia, PA, 2 Children’s Hospital of Philadelphia, Philadelphia, PA and 3 University of
Maastricht, Maastricht, Netherlands
Generalized arterial calcification of infancy (GACI) is an autosomal recessive disorder character-
ized by extensive premature calcification of the large and medium sized arteries and periarterial
soft tissues leading to progressive arterial stenosis and early myocardial infarcts. The majority of chil-
dren die within the first six months of life. Most cases of GACI are caused by inactivating mutations
in the ENPP1 gene. In this study, we first examined two siblings from a non-consanguineous fam-
ily who had GACI and normal ENPP1 gene sequences. To discover the disease-causing gene, we
identified genomic regions with sequence homology shared between the two affected siblings but
not their unaffected parents or brother. Within a small region of homozygosity shared by the affected
siblings we identified ABCC6 as a candidate gene, which is mutated in patients with pseudoxan-
thoma elasticum (PXE). Direct sequencing of ABCC6 revealed that the two affected siblings were
homozygous for the missense mutation p.R1314W, while their parents and an unaffected brother
were heterozygous. Sequencing of three additional unrelated patients with GACI and with normal
ENPP1 sequences revealed biallelic ABCC6 mutations. Humans with PXE and mice with targeted
ablation of the Abcc6 locus develop extensive mineralization of peripheral connective tissues, includ-
ing arterial blood vessels. Thus, our findings suggest a role for the ABCC6 gene product in inhibit-
ing arterial calcification under physiologic conditions, and they confirm a second locus for GACI.
Collectively, our data indicate that GACI and PXE can be allelic, underscoring the presence of an
intricate mineralization/anti-mineralization network in skin and other connective tissues.
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Diverse TGF-beta signalling activation in fibroblasts from phenotypically discordant monozy-
gotic twins with recessive dystrophic epidermolysis bullosa
M Di Salvio,1 E Piccinni,1 G Di Zenzo,1 A Orecchia,1 F Cianfarani,1 A Conti,2 G Zambruno,1
T Odorisio1 and D Castiglia1 1 Istituto Dermopatico dell’Immacolata-IRCCS, Rome, Italy and
2 Azienda Ospedaliera Universitaria Policlinico Modena, Modena, Italy
Dystrophic epidermolysis bullosa (DEB) is a rare blistering disease due to COL7A1 mutations. The
same genetic lesion can be associated with significant variability in inter- and intra-familial clini-
cal expression. The molecular basis of this variability is largely unknown. We here analysed a monozy-
gotic twin pair affected by recessive DEB (RDEB), expressing similar levels of type VII collagen but
showing markedly different phenotypic manifestations. Genome-wide expression analysis in twins’
fibroblasts showed differential expression of genes associated with TGF-beta signalling pathway
inhibition. Precisely, the less affected twin expressed increased interleukin-7 (IL-7), dermatopontin,
decorin, ID-1 and ID-2. Accordingly, fibroblasts from the more affected twin manifested a profi-
brotic phenotype characterised by enhanced alpha-smooth muscle actin (alpha-SMA) and plas-
minogen activator inhibitor 1 (PAI-1) expression, collagen I release, proliferation and collagen lat-
tice contraction. Moreover, fibroblasts of the more affected twin released increased amounts of IL-6
and MCP-1, which are proinflammatory cytokines overexpressed in fibrotic conditions. Both TGF-
beta canonical (Smads) and non canonical (MAPKs) pathways were basally more activated in the
cells of the more affected twin, and the response to TGF-beta was decreased in the cells isolated
from the sibling with milder phenotype. Fibroblast-conditioned media of the two patients were not
able to induce reciprocal phenotype reversion. However, when fibroblasts of the more affected twin
were cultured in the decorin-rich extracellular matrix (ECM) secreted by the less affected twin fibrob-
lasts, alpha-SMA expression was inhibited. In conclusion, our data indicate that ECM components
affecting TGF-beta signalling might prevent the profibrotic phenotype of RDEB patients thus miti-
gating the clinical manifestations.
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Identification of gain-of-function STAT1 mutations in patients with chronic mucocutaneous
candidiasis
J Hiller,1 S Eyerich,1 K Eyerich,1 M Schaller,2 J Casanova,3 S Cypowyj,3 A Puel,4 J Ring,5
H Hofmann5 and C Traidl-Hoffmann1 1 Center of Allergy and Environment (ZAUM), Technische
Universität and Helmholtz Zentrum München, Munich, Germany, 2 Department of
Dermatology, Eberhard-Karls-Universität, Tübingen, Germany, 3 St. Giles Laboratory of
Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New
York, NY, 4 Laboratory of Human Genetics and Infectious Diseases, Neckar Branch, Institut
National de la Sante et de la Recherche Medicale and University Paris Descartes, Paris, France
and 5 Department of Dermatology and Allergology, Technische Universität München,
Munich, Germany
Chronic mucocutaneous candidiasis (CMC) constitutes a selective inability to clear infection with
the yeast Candida albicans resulting in persistent inflammation of skin, nails, and mucous mem-
branes and is maybe caused by autosomal dominant IL-17F deficiency or autosomal recessive IL-
17RA deficiency. 2 CMC patients and their healthy relatives were investigated for STAT1 mutation
using whole-exome sequencing and IFN-γ stimulated PBMCs of these patients were analyzed in a
STAT1 TransAM. PBMCs of CMC patients and healthy controls were stimulated with Candida or
PHA and naïve T cells of both groups were differentiated to Th17 cells; cytokine production quan-
tified by ELISA. Whole-exome sequencing revealed that the tested CMC patients carried the STAT1
mutant alleles Q271P and R274W. These gain-of-function STAT1 alleles affect the coiled-coiled
domain and impair the nuclear dephosphorylation of activated STAT1. IFN-γ treated PBMCs of these
patients showed an increased STAT1 activity compared to healthy controls. Importantly, T cells
from CMC patients secreted significantly lower amounts of Th17-associated cytokines IL-17A and
IL-22 in response to Candida compared to healthy controls and Th17 differentiation was impaired
in CMC patients. These data indicate that the inability to clear the yeast Candida albicans in CMC
patients can be caused by gain-of-function STAT1 mutations which might impair IL-17 immunity
by enhancement of STAT1-mediated cellular responses.
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Comparative genome-wide transcriptome analysis reveals novel human skin-associated genes
encoding membrane and secreted proteins
P Gerber,1 P Hevezi,2 BA Buhren,1 C Martinez Reyes,1 H Schrumpf,1 B Homey1 and A Zlotnik2 1
Dermatology, University of Duesseldorf, Duesseldorf, Germany and 2 Physiology and
Biophysics, University of California, Irvine, CA
Using a genome-wide database of gene expression representing 105 different adult human tissues,
we were able to conduct the most comprehensive genetic profiling of the normal human skin to
date. We identified 689 skin-associated genes (SAGs) that are highly expressed in skin as compared
to all other tissues. Of the top 100 SAGs, 66 encode known skin markers, 25 are known genes not
previously associated with the skin and, most significantly, 9 encode uncharacterized proteins. High
levels of skin-associated expression of eight selected uncharacterized SAGs, that encode either
secreted or plasma membrane-associated proteins, was confirmed using qPCR and a panel of nor-
mal tissue and skin-derived primary cell RNAs. Two membrane protein SAGs, GPR87 and GPR115,
and two secreted protein SAGs, WFDC5 and SERPINB7, were expressed exclusively by keratinocytes.
Finally, WFDC5, GPR115 and TMEM45A protein expression was confirmed by immunohistochemistry
on human skin sections. Our study provides a comprehensive molecular profile of human skin and
identifies candidate novel genes for further investigation in skin diseases.
519
Biodegradable and Cationic Polymer Coupled with Minicircle COL7A1 DNA for the Correc-
tive Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa
A Aied, E Murauer, X Hu, L Cutlar, Y Zheng, A Pandit and W Wang National University of Ireland,
Galway, Galway, Ireland
Recessive Dystrophic Epidermolysis Bullosa is an inherited disease characterized by severe blister-
ing of the cutaneous tissue after mild trauma caused by a missing anchoring protein called Colla-
gen type VII (gene: COL7A1). Here we aim to provide corrective gene therapy of RDEB using a
cationic polymer to reintroduce the COL7A1 sequence (in the form of miniature plasmid known as
minicircle, MC-COL7A1) into skin cells by topical application. Polymer synthesis: The polymer
was synthesised by Deactivation Enhanced Atom Transfer Radical Polymerisation and characterised
by chromatography (GPC) and proton Nuclear Magnetic resonance (1H NMR). Organotypic skin
culture and transfection: Fibroblasts and keratinocytes (Keratinocyte Growth Medium II, Promo-
cell) from RDEB patients were embedded or seeded in a fibrin gel-matrix, respectively. After 28
days in culture at the air-liquid interface, the skin equivalents were transfected with the polymer/MC-
COL7A1 polyplexes and analysed for protein expression 48hrs later. Analysis: Collagen VII expres-
sion in skin equivalents was analysed using indirect immunofluorescence and western blot. Mon-
oclonal LH7.2 mouse antibody (Sigma) specific for human Collagen VII was used in all cases. Alexa
Flour® 488 IgG (H+L, Invitrogen) donkey-anti-mouse was used as the secondary antibody along
with 4’, 6-diamidino-2-phenylindole (DAPI) to identify the nucleus. Cells treated with polymer/MC-
COL7A1 polyplexes showed collagen type VII expression levels similar to those in normal human
keratinocytes and fibroblasts. The results suggest direct treatment of RDEB using a topically applied
polymer/MC-COL7A1 polyplexes is possible and has a potential therapeutic application.
520
Genetic Risk Variants for Psoriasis in a Large Case-Control Cohort and Association with Clin-
ical Subphenotypes
C Ferrandiz,1 E Fonseca,2 P Unamuno,3 J Hernanz,4 E Dauden,5 J Sanchez-Carazo,6 J López
Estebaranz,7 D Moreno-Ramírez,8 F Vanaclocha9 and L Puig10 1 Dermatology Service, H U
Germans Trias i Pujol, Badalona, Spain, 2 Dermatology Service, C H Juan Canalejo, A Coruña,
Spain, 3 Dermatology Service, H U de Salamanca, Salamanca, Spain, 4 Dermatology Service,
H U Gregorio Marañón, Madrid, Spain, 5 Dermatology Service, H U La Princesa, Madrid,
Spain, 6 Dermatology Service, H G U de Valencia, Valencia, Spain, 7 Dermatology Service, H
U Fundación Alcorcón, Madrid, Spain, 8 Dermatology Service, H U Virgen Macarena, Sevilla,
Spain, 9 Dermatology Service, H U 12 de Octubre, Madrid, Spain and 10 Dermatology
Service, H Santa Creu i Sant Pau, Barcelona, Spain
Background: Psoriatic Arthritis (PsA) is a complex disease with a substantial genetic risk compo-
nent. Recently, Genomewide Association Studies (GWAS) have expanded the number of risk loci
for Psoriasis (Ps) in >20 new loci. Objectives: We have studied the association of Ps risk loci in PsA
and purely cutaneous Ps (PsC). We have also analyzed the genetic association with several sub-
phenotypes of clinical relevance. Methods: Loci showing the strongest statistical evidence of asso-
ciation to Ps were selected (n=32) and genotyped in a cohort of n = 955 PsA, 1,050 PsC and 1,497
hypernormal controls of the Spanish population. Results: We have replicated the association to
COG6 and SERPINB8 loci with Ps for the first time in a Caucasian population. We have identified,
for the first time, an association of PsA with variation at IFIH1, DPP6 and COG6. Analyzing the
association with other clinically relevant subphenotypes we have identified a strong association of
LCE3D locus with the severity of cutaneous affection. We have also found a significant association
of IL1RN gene with nail disease. We replicated the previously described interaction of HLA-C and
ERAP1 in the PsC cohort but not in the PsA cohort. We identified, for the first time, a significative
epistatic association between HLA-C and SERPINB8. Conclusions: Our findings show that com-
mon genetic variants associated to a complex phenotype like PsV influence PsA as well as differ-
ent subphenotypes of high clinical relevance.
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Warfarin Accelerates Connective Tissue Mineralization in Abcc6-/- Mice – Relevance to Path-
omechanisms of Pseudoxanthoma Elasticum
Q Li,1 H Guo,1 LJ Schurgers2 and J Uitto1 1 Dermatology and Cutaneous Biology, Jefferson
Medical College, Philadelphia, PA and 2 Biochemistry, University of Maastricht, Maastricht,
Netherlands
Pseudoxanthoma elasticum (PXE), a heritable disorder characterized by extensive connective tissue
mineralization, is caused by mutations in the ABCC6 gene. Abcc6-/- KO mice recapitulate the PXE
phenotype, including mineralization of dermal sheath of vibrissae which serves as an early and
progressive biomarker. Previous studies have suggested a role for matrix Gla-protein (MGP) which
in its fully active γ-carboxylated form serves as a powerful tissue inhibitor of mineralization. The
activation of MGP is catalyzed by γ-glutamyl carboxylase, a vitamin K-dependent enzyme. To test
the potential role of MGP in the pathogenesis of PXE, we fed Abcc6-/- and control mice with diet
supplemented with warfarin, an inhibitor of γ-glutamyl carboxylase. The mineralization phenotype
was assessed by direct assay of calcium/phosphate content of the skin, as well as by histopathol-
ogy of the dermal sheath of vibrissae and various internal organs. The results demonstrated that feed-
ing of control mice with warfarin resulted in minimal tissue mineralization. The Abcc6-/- mice fed
normal diet demonstrated significantly increased mineralization (~5-fold), and feeding these mice
with warfarin further increased the mineralization by ~13-fold (p < 0.01). These increases were
reflected in the number of vibrissae mineralized per mouse assessed by histopathology and com-
puterized morphometry. Internal organs demonstrated significant mineralization, particularly in
the heart and kidney, in Abcc6-/- mice on normal diet, but supplementation with warfarin resulted
in massive mineralization essentially of all internal organs. Thus, the results indicate that Abcc6-/-
mice demonstrate ectopic mineralization, but this process is significantly accelerated by dietary
warfarin. Our results suggest that in addition to reduction in MGP anti-mineralization capacity,
MGP-independent mechanisms contribute to tissue mineralization. These findings also imply that
PXE patients should avoid warfarin.
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Functional Correction of Mutations in COL7A1 in a RDEB Patient Cellline via 5’ trans-splic-
ing
E Mayr, U Koller, EM Murauer, C Gruber, M Kaiser, A Klausegger, H Hintner and JW Bauer
Department of Dermatology, Division of Molecular Dermatology and EB-House Austria,
Paracelsus Private Medical University, Salzburg, Austria
Mutations in COL7A1, the gene coding for type VII collagen, are the cause of dystrophic epider-
molysis bullosa (DEB), a heritable mechanobullous skin disease. Because of its size the COL7A1
gene exceeds the integration capability of most viral vectors commonly used for delivery in gene
therapy. Furthermore endogenous regulation of expression is crucial in tissues with a complex dif-
ferentiation program. Therefore we chose a mRNA based gene therapy to repair defects in COL7A1.
RNA trans-splicing molecules (RTMs) containing specific binding domains for COL7A1 and the
wildtype sequence of the 5’ part of COL7A1 were virally transduced into recessive DEB (RDEB)
patient cells. Recovery of wildtype COL7A1 mRNA levels was detected in sqRT-PCR. Type VII col-
lagen protein staining comparable to wildtype was shown via immunofluorescence analysis of RTM
transduced RDEB patient cells. Moreover we could demonstrate correct localization of the recov-
ered protein within a tissue context in skin equivalents constructed from RTM transduced RDEB
patient cells. The long term goal of this approach is ex vivo gene therapy, in which skin grafts taken
from DEB patients are transduced with specific 5’ RTMs and are then transplanted back to the
patients.
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Spontaneous amelioration of junctional epidermolysis bullosa due to preferential alternative
splicing of the LAMB3 gene
K Karolak, MF Jonkman and AM Pasmooij Center for Blistering Diseases, Department of
Dermatology, University Medical Center Groningen, University of Groningen, Groningen,
Netherlands
Genetic mutation analysis is an essential element in determining patient prognosis in epidermoly-
sis bullosa. Correlation of mutation and corresponding phenotype is fundamental in determining
the clinical course of the disease and is of vital importance to both the physician and patient. We
studied a patient with spontaneous amelioration of junctional epidermolysis bullosa non-Herlitz
(JEB-nH). Immunofluorescence microscopy of skin biopsies, DNA analysis of peripheral blood, and
mRNA-analysis of cultured keratinocytes was performed. A 4-week-old male presented with gen-
eralized blister formation, nail dystrophy and severely reduced immunofluorescence staining for the
basement membrane protein laminin-332 in the blister of a skin biopsy. At the age of approxi-
mately 2 years, he was devoid of skin lesions, had mild nail dystrophy, and moderate expression of
laminin-332. Mutation analysis revealed compound heterozygosity for two mutations in the LAMB3
gene: a splice-site mutation c.628G>A in exon 7 and a non-sense mutation c.1903C>T in exon 14.
The c.628G>A mutation is known to result in different mRNA transcripts from which some are in-
frame. This patient’s phenotype was unexpectedly mild when compared with another JEB-nH patient
with the same mutations. To investigate a possible mechanism to explain this difference in clinical
severity, cDNA extracted from cultured keratinocytes from these patients was studied, as well as
from two other patients, who were homozygous for the c.628G>A mutation. Analysis of the proband’s
cDNA at one year of age suggested preferential splicing for more in-frame transcripts surrounding
the exon 7 mutation c.628G>A, which could have led to the spontaneous amelioration of the JEB-
nH phenotype. It is important to further identify the underlying mechanisms for this preferential in-
frame splicing as it could provide insights for splicing therapies.
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Rare Subtypes of Epidermolysis Bullosa Simplex: Molecular Criteria for Diagnosis
M Pigors,1 D Kiritsi,1 C Cobzaru,1 A Schwieger-Briel,1 J Suárez,2 F Faletra,3 I Tantcheva-Poor,4
C Wessel,5 L Bruckner-Tuderman1 and C Has1 1 Dermatology, University Freiburg - Medical
Center, Freiburg, Germany, 2 Dermatology, University Hospital Nuestra Señora de Candelaria
Carretera del Rosario, Santa Cruz de Tenerife, Spain, 3 Institute for Maternal and Child Health
IRCCS “Burlo Garofolo”, Trieste, Italy, 4 Dermatology, University of Cologne, Cologne,
Germany and 5 Dermatology, University of Hamburg, Hamburg, Germany
Epidermolysis bullosa simplex (EBS) is a heterogeneous group of genetic mechanobullous disor-
ders characterized by intra-epidermal cleavage. The vast majority of EBS cases is caused by domi-
nantly inherited mutations in the genes for keratin 5 or 14, but in approximately 25% of patients
no mutations can be disclosed in these genes. The aim of this study was to elucidate the genetic
background in a cohort of 60 patients with suspected EBS without keratin defects by screening muta-
tions in other EBS-associated genes, including plectin (PLEC), exon 31, and BPAG1e (DST). Since
mutations in the gene for transglutaminase 5 (TGM5) cause acral peeling skin syndrome (APSS), a
rare genetic entity that resembles EBS particularly in young individuals, this gene was included in
the screening. Eight affected individuals of three unrelated families were diagnosed with the dom-
inant EBS-Ogna subtype caused by the unique PLEC mutation, p.R2000W. Characteristic for EBS-
Ogna skin was reduction of the plectin immunofluorescence signal with rod-domain specific anti-
bodies, combined with reduced and interrupted staining of other hemidesmosomal components.
Thirteen patients with APSS carrying recurrent and previously unreported TGM5 mutations were
identified. Immunofluorescence and -blotting analysis showed that TGM5 mutations significantly
altered the expression of epidermal differentiation markers and corneodesmosin in APSS keratinocytes
and skin. No DST mutations were found. Taken together, the screening unravelled the genetic defects
in 30% of the suspected EBS cases, and demonstrated that the specific findings in APSS and EBS-
Ogna represent useful molecular criteria that facilitate the diagnosis of these commonly unrecog-
nized skin fragility disorders.
526
Papillon-Lefèvre syndrome ; total loss of cathepsin C activity may be required for disease
expression
N Takiyoshi,1 D Matsuura,2 A Umekoji,3 M Furuichi,4 T Shimizu,4 T Fukui,1 H Nakano,1
D Sawamura1 and T Ochiai2 1 Dermatology, Hirosaki University Graduate School of Medicine,
Hirosaki, Japan, 2 Dermatology, Nihon University Surugadai Hospital, Tokyo, Japan, 3
Dermatology, Osaka Kaisei Hospital, Osaka, Japan and 4 Dermatology, Graduate School of
Medicine and    Pharmaceutical Sciences, University of Toyama, Toyama, Japan
Papillon-Lefèvre syndrome (PLS) is a rare autosomal recessive disorder characterized by palmo-
plantar keratosis (PPK) and early-onset periodontitis that leads to the loss of primary and secondary
teeth. PLS is caused by mutations in the gene coding for cathepsin C (CTSC). CTSC is a lysosomal
cysteine proteinase that activates many serine proteinases in immune/inflammatory cells. So far,
there have been more than 70 different CTSC mutations reported. Here, we performed mutational
analyses of CTSC in four Japanese families with PLS and identified five novel mutations. The CTSC
activities of the three probands were hardly detectable. We also conducted functional analyses of
a single nucleotide polymorphism (SNP); c.1357 A>G (p.I453V) in CTSC. The genotypic frequency
of the SNP in homozygous state is very rare in the Western countries. In the present study, we deter-
mined that 15.7% of Japanese healthy controls (n=70) were heterozygotes for c.1357G and only
4.3% were homozygotes. Compared to controls homozygous for c.1357A, the CTSC activity was
50% in individuals heterozygous for c.1357G, while that was only 10% in those homozygous for
c.1357G. Interestingly, all the homozygotes for the SNP examined had no symptoms of PPK and
periodontitis compatible with PLS. These findings strongly suggest that the disease expression of PLS
requires nearly total loss of the CTSC activity.
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Cell-Based Therapeutics for Pseudoxanthoma Elasticum
Q Jiang,1 S Takahagi,1 Y Zhou,1 G Bilousova,2 D Wang,1 D Roop2 and J Uitto1 1 Dermatology and
Cutaneous Biology, Jefferson Medical College, Philadelphia, PA and 2 Dermatology, and
Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of
Colorado, Aurora, CO
Aberrant mineralization of peripheral connective tissues is a characteristic feature of pseudoxan-
thoma elasticum (PXE), a heritable metabolic disorder caused by mutations in the ABCC6 gene.
This gene, which encodes an ABC transmembrane efflux transporter, is expressed primarily in the
liver. There is currently no effective treatment for PXE. In this study, we have investigated the poten-
tial of induced pluripotent stem cells (iPSCs), the whole bone marrow (BM), and bone marrow
derived mesenchymal stem cells (MSCs) for liver regeneration, with the aim to rescue PXE pheno-
type in Abcc6-/- mice, a model system that recapitulates the genetic, histopathologic, and ultra-
structural features of PXE. First, we characterized mouse fibroblast-derived iPSCs, BM and purified
MSCs, which were derived from GFP+ transgenic mice, and we demonstrated that iPSCs and MSCs
types have the capability of differentiating into hepatic lineages, hepatoblasts and hepatocytes in
vitro. Secondly, we demonstrated the capabilities of MSCs to home to the liver after administration
through intravenous injection following partial hepatectomy with or without low dose irradiation.
Finally, we demonstrated that the interactions between CXCR4, a chemokine receptor, and its lig-
and SDF-1, a stem cell derived factor, could be critical for recruitment and homing of transplanted
cells for liver targeting. Theses therapeutic models provide a platform for translational application
of cell based liver reconstitution as a means of regenerative therapy for PXE.
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Over-expression and altered localisation of MDM2 in lamellar ichthyosis
G Youssef,1 M Ono,1 J Harper2 and R O’Shaughnessy1 1 Immunobiology and Dermatology, UCL
Institute of Child Health, London, United Kingdom and 2 Paediatric Dermatology, Great
Ormond Street Hospital NHS Trust, London, United Kingdom
Lamellar Icthyosis (LI) is an autosomal recessive disorder of defective epidermal barrier formation
resulting in hyperkeratosis and scaling. LI is a genetically heterogenous disorder; where mutations
in transglutaminase 1 (TGM1) and Lipoxygenase 12b (ALOX12B) account for around 50% of LI inci-
dence. The mechanisms of hyperkeratosis in this disease are not well defined. To address this we
generated an in vitro model of LI by transfecting rat epidermal keratinocytes (REK) cells with Tgm1
siRNA expressing plasmids. We performed array hybridisation analysis and Ingenuity Pathway Analy-
sis (IPA) and identified a network of interacting genes centred around keratins 1 and 10 and the p53
ubiquitin ligase MDM2. Western blot analysis in Tgm1 shRNA knockdown cells confirmed the coor-
dinate up-regulation of Keratin 1and MDM2 and down-regulation of Keratin 10. MDM2 overex-
pression was confirmed in patients with known defects in TGM1 function. MDM2 was localised in
the cytoplasm in control organotypics. In Tgm1 knockdown organotypic culture, MDM2 was
increased in expression and localised to the plasma membrane. In Alox12b knockdown organotypic
culture, there was no increase in MDM2 levels, but MDM2 was similarly localised to the plasma
membrane. Therefore we report that MDM2 up-regulation is diagnostic of LI caused by TGM1 muta-
tion, and that plasma membrane localisation of MDM2 may be a mechanism for the mis-regulation
of suprabasal keratin expression and therefore may contribute to hyperkeratosis. We propose that
MDM2 is not only a potential diagnostic marker, but also, due to the availability of MDM2 inhibitors
such as the nutlins, an attractive target for therapy.
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Double RNA trans-splicing induced gene correction in epidermolysis bullosa
U Koller,1 S Hainzl,1 A Klausegger,1 V Wally,1 EM Murauer,1 E Mayr,1 C Gruber,1 L Mitchell,2
H Hintner1 and JW Bauer1 1 Department of Dermatology, Division of Molecular Dermatology
and EB House Austria, Paracelsus Medical University, Salzburg, Austria and 2 RetroTherapy,
Bethesda, MD
RNA trans-splicing is an approach to reprogram genes for diagnostic and therapeutic purposes. For
correcting mutations in genes that cause genetic diseases, it is desirable to perform an exon-wise
strategy. This can be achieved by double RNA trans-splicing. Here we showed the correction of
mutations in the epidermolysis bullosa-associated genes COL17A1 and COL7A1. Using the target
gene COL17A1 we were able to demonstrate the functionality of an RTM screening system to
repair exon 52 by double RNA trans-splicing. Using a GFP-based cassette system were able to
identify highly specific RTMs inducing the gene repair on mRNA level by trans-splicing via two
binding domains, specific for the surrounding introns 51 and 53. The best RTMs lead to the expres-
sion of significant higher levels of GFP in up to 61% assayed cells. Another promising target for
double RNA trans-splicing is the gene COL7A1 with a transcript size of over 9kb. A double RNA
trans-splicing strategy enables the correction of internal COL7A1 exons and minimizes the size of
the RTM significantly, avoiding many size-associated hurdles. Co-transfection of the target mole-
cule, including the gene region intron 102 – exon 103 – intron 103 – exon 104 – intron 104 – exon
105 – intron 105 flanked by the 5’ and 3’ coding ends of GFP and the most efficient randomly
designed RTM, harboring the missing internal GFP sequence, into HEK293 cells, induced the restora-
tion of full-length GFP by trans-splicing in over 27% of analysed cells. We assume that RNA trans-
splicing is a promising tool to correct hot spot mutations in various genes, for which gene regula-
tion, gene size or the way of mutational inheritance are key factors for a therapeutic success.
529
A photoaging-like phenotype in dermal equivalents: evidence for proteasomal dysregulation
in KSS fibroblasts
B Schürmann,1 C Götz,1 M Majora,1 S Franke,1 M Schneider,1 F Bernerd2 and J Krutmann1 1 IUF
Leibniz Institute, Düsseldorf, Germany and 2 L’Oreal Recherche, Clichy, Paris, France
Mutations of mitochondrial (mt) DNA are frequently detected in aged tissues. It has therefore been
suggested that mtDNA mutations are causally related to the aging process, but mechanistic details
still remain largely unknown. We have previously shown that human dermal equivalents (DEs)
containing fibroblasts from Kearns-Sayre syndrome (KSS) patients harboring high levels of large scale
deletions of the mtDNA develop a phenotype resembling photoaged human skin. In comparison to
DEs containing normal human fibroblasts (NHF), KSS DEs show elevated levels of reactive oxygen
species (ROS), increased expression of the collagenase MMP-1 and progressive loss of intact col-
lagen fibers. Moreover, increased expression of VEGF, lysyl oxidase (LOX) and IL-8 was also noted
in KSS DEs. We now provide evidence that the photoaging-like phenotype in KSS DEs is caused by
dysfunction of the proteasome and postulate a functional link between mtDNA deletions, elevated
ROS levels, proteasomal activity and aberrant gene expression. To verify our hypothesis, KSS and
NHF DEs were treated with sulforaphane, a substance which is known to increase proteasomal activ-
ity. Sulforaphane treatment not only resulted in reduction of the elevated mtROS levels in KSS DEs
but also induced a significant reduction of MMP-1 expression in KSS DEs which was not seen in
NHF DEs. Moreover, it could also significantly reduce expression of VEGF, LOX and IL-8 in KSS
DEs but had no suppressive effect on the expression of these genes in NHF DEs. In contrast, expo-
sure to the proteasome inhibitor bortezomib resulted in substantially elevated mtROS levels and
strongly increased expression of MMP-1 in NHF DEs while KSS DEs were hardly affected by borte-
zomib. Taken together our data confirm recent studies proposing a functional interplay between
mitochondria and the proteasome. Moreover, they suggest a causal relationship between mtDNA
mutagenesis, increased ROS levels, proteasomal dysfunction, altered gene transcription and a pho-
toaging-like phenotype.
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Transcriptome analysis of atopic skin demonstrates the importance of extracellular mecha-
nisms in the filaggrin-related barrier defect
S Brown, C Cole, I McLean, G Barton and A Irvine Dermatology and Genetic Medicine,
University of Dundee, Dundee, United Kingdom
The skin of atopic eczema patients is characterised by a reduced threshold for inflammation and
widespread impairment of barrier function, not limited to areas of active eczema. Null mutations
in the gene encoding filaggrin (FLG) are associated with barrier dysfunction and increased risk of
eczema, but the mechanisms by which filaggrin deficiency results in these clinical features are
unclear. Whole transcriptome analysis was used to investigate genetic mechanisms in atopic skin.
4mm punch biopsies were collected from 26 Irish paediatric atopic eczema cases, sampling unin-
volved skin in order to study the primary abnormalities in the absence of secondary inflammation.
Direct RNA sequencing (Helicos BioSciences, Cambridge MA) gave accurate quantification of mRNA
and patients were genotyped for FLG null mutations. Seven cases were FLG wild type, 13 were het-
erozygous and 6 compound heterozygous. In this case/case comparison 261 genes from a total of
11,259 were differentially expressed (unadjusted p<0.01) between wild type cases and those with
FLG mutations. Gene Ontology (GO) analysis classified a significant number of genes in associa-
tion with the extracellular matrix (19 genes, FDR p=3.3x10-11) and extracellular space (n=27, FDR
4.5x10-10). After controlling for multiple testing 9 genes showed significant differential expression
(adjusted p<0.05): FLG, S100A9, S100P, CLU, CILP, C1QTNF1, IGFBP6, C16orf45 and
AC105402.4.1. GO analysis of these 9 genes again highlighted the significance of extracellular
space (p=1.45x10-3). Themes identified by manual search of published literature included calcium
binding motifs (FLG, S100A9, S100P) and apoptotic pathways (S100A9, CLU, IGFBP6). C1QTNF1
is a novel regulator of fatty acid metabolism but its role in skin is not known. This transcriptome
analysis has emphasised the importance of the extracellular space in filaggrin-deficient skin, adding
novel insight into mechanisms by which a paracellular barrier defect may result from insufficiency
of the intracellular molecule filaggrin.
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CSA and CSB proteins localize in a large multiproteincomplex involved in repair and tran-
scription of mitochondrial DNA: involvement for neurodegeneration
Y Kamenisch, S Giovannini, N Düzenli, J Knoch, M Röcken and M Berneburg Department of
Dermatology, Eberhard Karls University, Tuebingen, Germany
Cockayne syndrome is a rare progeroid disorder, characterized by sun sensitivity of the skin, pre-
mature loss of subcutaneous fat and neurodegeneration. CS is caused by dysfunctional CSA or CSB
proteins, which are involved in transcription and repair of nuclear DNA. We have previously shown,
that CSA and CSB proteins are also associated to the mitochondrial DNA protein complex (nucleoid)
and protect from stress or aging induced accumulation of mtDNA mutations and protect from
aging associated loss of subcutaneous fat tissue. It is known, that mutations of mitochondrial DNA
can cause aging symptoms, but less is known about the proteins which are associated to the mito-
chondrial DNA. The nucleoid is the structure in the mitochondria, where the mitochondrial DNA
and several protein complexes are located. In order to further investigate the role of mitochondrial
CSA and CSB proteins, we developed a new assay to screen mitochondrial nucleoids for protein
interaction partners. After isolation of mitochondria and subsequent precipitation of nucleoid com-
plexes, the different nucleoid complexes were separated and visualized by blue native gel elec-
trophoresis and proteins were detected by an additional second dimension SDS gel separation fol-
lowed by western blot analysis. We found that CSA and CSB containing protein complexes also
harbor the proteins, which are essential for mitochondrial transcription: mtRNA polymerase and
mitochondrial transcription factor A (mtTFA). In addition we found a protein involved in the patho-
genesis of Parkinson disease also in the CSA and CSB associated mtDNA protein complex. These
findings point to a role of mitochondrial CSA and CSB in mitochondrial transcription, and provide
evidence that Parkinson relevant mitochondrial proteins could play a role in the CSA and CSB pro-
tein containing nucleoid complex.
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Bone Marrow Cell Therapy for the Treatment of Epidermal Skin Defects in Desmoglein-3
Knockout Mice
C Hünefeld,1 M Mezger,2 E Müller-Hermelink,1 K Fuchs,1 R Handgretinger2 and M Röcken1 1
Department of Dermatology, Eberhard Karls University, Tübingen, Germany and 2
Department of General Paediatrics, Haematology and Oncology, University Children’s
Hospital, Tübingen, Germany
Epidermolysis bullosa (EB) is characterized by blistering and erosions induced by minimal trauma
or shearing forces. Due to recent reports, transfer of defined bone-marrow cells seems to be a
promising therapy. To address this question for a disease with an exclusive epidermal skin defect in
keratinocytes, we used Desmoglein-3 (Dsg-3) knockout mice to investigate the potential of bone
marrow transplantation (BMT) and defined bone-marrow stem cell populations as a new therapy
option. BMT of EGFP or DsRed expressing Dsg3+/+ donor cells resulted in blood and bone mar-
row chimerism of approximately 80%. Interestingly, optical imaging allowed us to demonstrate
that a remarkable number of bone marrow cells migrated into the epidermis 6 or 10 weeks after
transplantation. Analyzing these cells isolated from the dorsal epidermis by FACS about 1% EGFP
or DsRed positive donor cells were detected. Surprisingly, all of the donor cells expressed the
haematopoietic marker CD45 on the surface and no transdifferentiation of bone marrow cells into
keratinocytes, particularly integrin alpha 6 positive cells, was observed. To confirm these observa-
tions, the CD45 positive cells from the epidermis were selectively sorted by FACS and analyzed for
the presence of the Dsg-3 wild type allele by PCR. Only the CD45 positive population showed an
intact Dsg-3 allele, whereas the CD45 negative cells did not. Furthermore, in keratinocyte cultures
isolated from the dorsal skin of transplanted Dsg-3 knockout mice, no EGFP or DsRed positive ker-
atinocytes were present. In addition, no Dsg-3 expression in transplanted mice could be detected
when analyzing skin tissue samples by qRT-PCR, Western Blot and immunohistology. In conclusion,
BMT was not able to mediate restoration of Dsg-3 expression under classical BMT in adult, albeit
a remarkable number of donor cells were detectable in the epidermis.
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Imbalances of epidermal proteases are found in ichthyosis vulgaris and may have role for
eczema susceptibility
I Zaraeva,1 A Perusquia,1 K Aufenvenne,1 T Tarinski,1 N Seller,1 D Breitkreuz,2 I Hausser,2
H Traupe1 and V Oji1 1 Department of Dermatology, Muenster, Germany and 2 Department of
Dermatology, Heidelberg, Germany
Ichthyosis vulgaris (IV) is a common genetic skin disease due to filaggrin (FLG) deficiency. FLG muta-
tions cause a lack of natural moisturizing factor and are strongly predisposing to atopic dermatitis
(AD). A slight elevation of the stratum corneum (SC) pH has been shown by some groups. We have
clinically studied a cohort of IV patients and conducted a skin physiological study on transepider-
mal water loss (TEWL), pH and corneometry. 3D keratinozytic models of complete FLG deficiency
(n=6) were developed and were analysed for expression and activity of KLK5, KLK7, caspase-1
(CASP1), as well as expression of the serine protease inhibitor LEKTI and interleukin-1b (IL-1b).
TEWL was increased in IV (p<0.03), skin hydration was decreased (p<0.05); pH showed a slight
non-significant increase (IV group: 5.54,sd=0.14). 3D models showed an increase of KLK7 expres-
sion (p<0.001) and activity (p<0.0001) in non-eczema subgroup, whereas KLK5 activity was not
significantly elevated. There was no shift of LEKTI expression, but we observed high levels of pro-
IL-1b in FLG-/- models (p<0.0001). Interestingly, an increase of CASP1 activity was detected in 3D
models of eczema-subgroup (p<0.0001), whereas those from non-eczema subgroup showed a
decrease (p<0.05). To confirm results of 3D models, we analysed tape strips of IV patients (n=11)
and controls (n=8). KLK5- as well as KLK7-activities in scales correlated well with those from cell
culture. Expression/activity of CASP1 was not detectable suggesting a very low expression of CASP1
in the upper SC. In search of the pathophysiologic relation between IV and AD we assume an impor-
tant role of KLK activities. Considering the small sample size of the study significant increases of
KLK7 are surprising. They may contribute to eczema susceptibility independent from eczema
immunology. Moreover, in view of the 3D models, it is tempting to speculate about an eczema-
protective mechanism in IV, which could be associated with CASP1 activation cascade.
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Recessive epidermolysis bullosa simplex due to plectin 1a deficiency causes only skin blisters
MF Jonkman1 and HH Lemmink2 1 Dermatology, UMCG, Groningen, Netherlands and 2
Genetics, UMCG, Groningen, Netherlands
Plectin is a major crosslinking element of the cytoskeleton, and plays an essential role in epithelial
tissues, myocardium, and striated muscle. Its deficiency may result in epidermolysis bullosa sim-
plex associated with cardiomyopathy, muscular dystrophy, or pyloric atresia. It is the only gene in
the genome that has multiple isoforms, which only differ by unique exon 1 and corresponding 5’
transcription regulatory sequences. In human, eight isoforms are known, of which plectin 1a, 1c, 1
and 1b are expressed in primary keratinocytes. In mice, plectin 1a is the only isoform that localize
to the basement membrane zone (BMZ) of the epidermis. Here we present the first human pheno-
type that is caused by isolated plectin 1a deficiency. A 27-year-old Turkish woman with consan-
guinous parents had a mechanobullous skin disorder that started at her feet when walking at the
age of 1.5 y. Blistering became generalized at puberty. Mucous membranes were not affected, nor
were hair and teeth. Nails were curved and thickened. Electron microscopy showed hypoplastic
hemidesmosomes, and an intra-epidermal ‘pseudojunctional’ split with the plasma membrane on
the blister floor. Antigen mapping with moab HD-121 against the common plectin rod domain
revealed unreduced staining, but with moab 10F6 staining was reduced along epidermal BMZ and
pericellular epidermis. DNA sequencing revealed an homozygous nonsense mutation (c.46c>T;
p.Arg16X) in exon 1 of the plectin 1a isoform. Screening for cardiomyopathy and muscle dystro-
phy showed no abnormalities. Epidermolysis bullosa simplex due to isolated plectin 1a deficiency
is an autosomal recessive disorder that only affects skin, while heart, muscle and mucous mem-
branes are clinically not affected. The persistant expression of common plectin epitopes in the epi-
dermal BMZ of the patient suggests that in human, but not in mice, other plectin isoforms are co-
expressed in the epidermal BMZ. However, the intensification of skin blistering of the patient until
the age of 18 years implies that the role of plectin 1a rises with growth.
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Optimized high throughput screening system for RNA trans-splicing molecules for gene cor-
rection in epidermolysis bullosa
S Hainzl, U Koller, E Murauer, B Tockner, V Wally, H Hintner and J Bauer Department of
Dermatology, Division of Molecular Dermatology and EB House Austria, Paracelsus Medical
University, Salzburg, Austria
Spliceosome Mediated RNA Trans-splicing (SMaRT) is a pre-mRNA based gene therapy approach
that exploits the naturally occurring splicing machinery in order to replace one or more exons of a
mutated pre-mRNA. Gene replacement by trans-splicing is initiated by a RNA transsplicing mole-
cule (RTM), that is designed to comprise an antisense binding domain (BD) for the targeted intron.
We want to use SMaRT in order to correct genes associated with the inherited skin disease epider-
molysis bullosa (EB). Up to now our corrective RTMs were designed in a single-shot approach. To
improve the therapeutic efficacy we have established a fluorescence-based screening method for
the identification of highly efficient RTMs by fluorescent-based cell sorting. Their functionality was
tested in stable cell lines expressing respective target constructs. We have designed target con-
structs for three main EB genes (COL7A1, COL17A1 and PLEC), each expressing the intron we
want to target and one half of a GFP reporter gene. The target constructs were integrated into the
genome of a HEK293 cells by retroviral transduction, mimicing an endogenous target pre-mRNA
at a constant level. For each target gene we have randomly created RTM libraries harboring com-
plementary binding domains for the respective target introns and the missing part of the GFP reporter
gene. After transfection of the RTM library, the splitted GFP parts are recombined by trans-splicing,
resulting in the expression of GFP. Cells with the highest GFP expression were sorted using a FACS
Sorter. Identification of highly functional RTMs is the key step towards a gene therapy for EB in
vivo.
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Mosaic SOSTDC1 downregulation alters ECM remodelling enzymes in Linear morphea fibrob-
lasts
SJ Brown,1 L Weibel,2 JI Harper3 and R O’Shaughnessy1 1 Immunobiology and Dermatology,
UCL Institute of Child Health, London, United Kingdom, 2 Dermatology, University of Zurich,
Zurich, Switzerland and 3 Paediatric Dermatology, Great Ormond Street Hospital, London,
United Kingdom
Linear morphea is a fibrotic disorder affecting children, where excessive collagen deposition causes
a localised hardening of the skin. The cause is currently unknown, but the disorders notable inci-
dence along the Lines of Blaschko, suggests an early mosaic fibroblast defect leading to disease in
the child. This study characterised the effects of the downregulation of SOSTDC1, a consistent fea-
ture of fibroblasts from affected regions of linear morphoea patients. The altered release of extra-
cellular remodelling proteins and ECM components was studied in 1) the dermis of a linear mor-
phea sufferer, 2) the supernatant of primary fibroblast cultures derived from affected and unaffected,
site matched areas and 3) fibroblasts expressing shRNA causing a downregulation of Sostdc1. As
well as direct visualisation, expression levels were surveyed by western, and activity of released fac-
tors was determined using zymography. In Linear morphea fibroblasts, expression of MMP2 was
upregulated compared to controls, with a concomitant increase in activity. The migration of LM
fibroblasts, as measured by scratch assay, was also increased relative to site matched controls. This
phenotype is a hallmark of ‘activated’ fibroblasts, an early differentiation step occurring after wound
injury, but before myofibroblast formation. The increase in MMP2 activity was mirrored in fibrob-
lasts engineered with reduced Sostdc1 expression. In conclusion, LM fibroblasts show altered pro-
liferation and migration, and cell-intrinsic differences in the production of ECM remodelling pro-
teins. Sostdc1 downregulation alone is sufficient to alter the expression and activity of ECM
remodelling molecules seen in Linear morphea fibroblasts. We propose that SOSTDC1 downregu-
lation is an important controlling factor in early fibroblast activation, could be a contributing fac-
tor in the Linear morphea phenotype, and presents a novel avenue of treatment for this disease
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Revertant mosaicism in children with non-Herlitz junctional epidermolysis bullosa
AM Pasmooij,1 M Garcia,2 MF Jonkman1 and M Del Rio2 1 Center for Blistering Diseases,
Department of Dermatology, University Medical Center Groningen, University of Groningen,
Groningen, Netherlands and 2 Regenerative Medicine Unit, CIEMAT and Centro de
Investigaciones Biomedicas en Red De Enfermedades Raras (CIBERER U714), Madrid, Spain
Revertant mosaicism refers to the co-existence of cells carrying inherited genetic mutations with
cells in which the inherited disease-causing mutation is corrected by a spontaneous genetic event,
thereby giving rise to a clinically healthy phenotype. This phenomenon of ‘natural gene therapy’
occurs in all Dutch patients with the genetic blistering disease non-Herlitz junctional epidermoly-
sis bullosa (JEB-nH) due to COL17A1 mutations. All patients had one or more clinically healthy (=
revertant) patches of skin where no blisters developed. The revertant patches did not significantly
change in size in adulthood. One patient, however, indicated that new patches had arised in child-
hood, though supportive photo-material was lacking. To learn more about this possible expansion
of revertant skin areas at a younger age, two children with JEB-nH were thoroughly investigated.
Both the 15-year-old female (COL17A1: c.2576dupC/c.3827dupC) and the 9-year-old male
(COL17A1: c.1260delC/c.3495-3496delCT) displayed several revertant patches. From each child
one biopsy was taken of a revertant patch to investigate the molecular reversion mechanism. A
gene conversion corrected the c.2576dupC mutation in the girl, whereas in the boy an additional
second-site mutation (c.3419G>T) led to in-frame skipping of exon 49 (90 bp) and resulted in
shortened type VII collagen protein. Extensive photo-material of the boy showed that at 6 years of
age different revertant patches could already be identified. In contrast to what was noted in adult-
hood, these patches changed in size between the age of 6 to 9 years. Some of the patches increased,
while other patches decreased. As revertant mosaicism has possible therapeutic options by using
the patient’s own naturally corrected keratinocytes, knowledge about the development of the rever-
tant patches is essential.
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Epidermolysis bullosa simplex: new phenotypes and PLEC genetic mutations
A Charlesworth,1 C Chiaverini,1 J Lacour3 and G Meneguzzi2 1 Reference Centre for Inherited
Epidermolysis Bullosa, Hospital Archet-2, Nice, France, 2 INSERM U1081-CNRS UMR 7284,
Nice, France and 3 IRCAN, Nice-Sophia Antipolis University, Nice, France
Genetic mutations in plectin gene (PLEC) cause autosomal recessive epidermolysis bullosa simplex
associated with either muscular dystrophy (EBS-MD) or pyloric atresia (EBS-PA). We report seven
new EBS patients, four of which with novel clinical phenotypes, and eleven novel PLEC mutations.
Patients presented hallmarks of inherited EBS: congenital cutaneous and mucous blistering with
healing without scarring, atrophy or milia. Two suffered from EBS-PA revealed in utero after prena-
tal ultrasound examination due to suspicion of polyhydramnios. Four patients displayed progres-
sive onset of muscular dystrophy. Interestingly, we report the first case of non-lethal EBS-PA improv-
ing with age; the first multisystemic involvement in lethal EBS-PA; the first EBS-MD cases with either
bladder or oesophagus involvement. In all cases, plectin defective expression was detected by
immunofluorescence studies of skin biopsies followed by molecular analysis of PLEC. Eleven novel
PLEC mutations were identified. Previous phenotype-genotype analysis suggested that EBS-MD is
due to genetic mutations essentially affecting the plectin central rod domain, and EBS-PA to muta-
tions outside this domain. Our results confirm that EBS-PA is linked to mutations in the distal PLEC
exons 1-30 and 32, whereas EBS-MD is linked to PLEC mutation in all exons. They unveil that long-
term survival of EBS-PA is possible, with skin improvement, and underscore that presence of severe
mucosal involvement(s) is not predictive of early MD onset. The precocity of muscular dystrophy
seems to be linked to type/localization of PLEC mutation, but no strong correlation with mucosal
involvement is found. However, patients affected by in-frame insertion/deletion mutation appar-
ently display milder EBS-MD phenotypes. Besides identification of novel PLEC mutations in EBS,
our results contribute to the establishment of genotype-phenotype relationship, and to ante- and
post-natal diagnosis of such a genetic condition.
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Gene profiling of drugs induced herpesvirus reactivation in B lymphoblastoid cell lines from
DRESS patients
SF Calbo,1 X Camous,1 B Janela,1 J Chen,1 E Chua,1 J Lum,1 F Zolezzi,1 M Poidinger1 and
P Musette2 1 Singapore Immunology Network, Agency for Science, Technology and Research,
Singapore, Singapore and 2 University of Rouen, INSERM U905, Rouen, France
Drug reaction with eosinophilia and systemic symptom (DRESS) is a severe drug-induced cutaneous
reaction with visceral involvement and blood abnormalities associated with reactivation of herpes-
virus family i.e., EBV, HHV-6, HHV-7 and CMV. Recently, we demonstrated that the immune response
in DRESS, previously thought to be directed against drug components, is also mediated by herpes-
virus specific cytotoxic CD8+ T lymphocytes which home to the skin and visceral organs. We ana-
lyzed the effect of the culprit drug on EBV reactivation. An in vitro model based on EBV-trans-
formed B lymphoblastoid cells lines from DRESS patients and healthy donors were used to study
the specific effect of drugs on EBV titre. Gene expression profiles were obtained for cell lines
treated or not by allopurinol, amoxicilline, sulfamethoxazole, valproic acid or carbamazepine. Sig-
nificant differential gene expressions were found in DRESS patients’ cell lines. We confirmed the
increase of gene level expression at the protein level, especially for TNFa. Finally, we performed
functional assay to address the role of this gene on the effect on immune response by setting up in
vitro assay. Our results suggest a new role for drugs in the pathogenesis of DRESS.
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The identification of fifteen novel psoriasis susceptibility loci highlights the skin’s role in innate
immune defense
RC Trembath,1 G Abecasis,2 JT Elder,2 O of Psoriasis,2 T Association Genetics Extension,2
T Psoriasis Consortium3 and A Consortium 23 1 Queen Mary University of London, Barts and
the London School of Medicine and Dentistry, London, United Kingdom, 2 University of
Michigan, Ann Arbor, Michigan, MI and 3 Division of Genetics and Molecular Medicine,
King’s College London, London, United Kingdom
The existence of a genetic component underlying the pathogenesis of psoriasis has long been rec-
ognized and genome-wide association studies (GWAS) of Caucasian populations have successfully
identified 19 susceptibility loci. To gain further insights into the genetic architecture of the disease,
we conducted a meta-analysis across three case-control resources examined in previous GWAS and
two independent datasets genotyped on the Immunochip (a custom genotyping platform including
~200,000 immune-related SNPs). The analysis of 10,588 cases and 22,806 controls identified 15
novel psoriasis susceptibility regions and 5 independent signals mapping within previously known
loci. Shared disease intervals overlapped most often with Crohn’s disease loci and encompassed a
number of T-cell related genes (e.g. RUNX3, TAGAP and STAT3). Conversely, psoriasis-specific sus-
ceptibility regions were notable for candidates involved in innate host defense. These included genes
contributing to interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C),
and NF-κB signaling (CARD14, CARM1). These results contribute to a better understanding of shared
and distinctive genetic determinants of immune-mediated disorders and emphasize the impor-
tance of innate defense in the pathogenesis of psoriasis.
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Screening for highly efficient RTMs to improve 3’ trans-splicing for COL7A1 gene
B Tockner, EM Murauer, E Mayr, V Wally, U Koller, S Hainzl, H Hintner and JW Bauer Department
of Dermatology, Paracelsus Medical University, Salzburg, Austria
Mutations in the COL7A1 gene cause functional defects of type VII collagen, the major component
of anchoring fibrils within the basal membrane zone of the skin. Loss of function of the protein leads
to the inherited skin fragility disorder dystrophic epidermolysis bullosa (DEB). Gene therapy efforts
for DEB are still accompanied by a number of technical challenges due to the size of the COL7A1
transcript (> 9 kb). Spliceosome Mediated RNA trans-splicing (SMaRT) may serve as an repair strat-
egy overcoming this obstacle. Using a fluorescent-based screening system we are able to identify
most efficient RNA-trans-splicing molecules (RTMs) with improved binding properties for the tar-
get Intron 46 of the COL7A1 gene. Most efficient RTMs binding to Intron46/Exon47 of COL7A1
were able to induce specific trans-splicing in up to 95% of RTM and target expressing cells. The
identified RTMs with high efficiency differ in length and localization of the specific binding site
within the Intron 46 of the COL7A1 pre-mRNA. The identification of the most functional RTM will
improve trans-splicing in the COL7A1 gene in order to lay the basis for gene therapy of DEB patients.
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Conditional Analysis Identifies Three Novel Major Histocompatibility Complex Loci Associ-
ated With Psoriasis
J Knight,1 SL Spain,2 F Capon,2 JN Barker,3 ME Weale2 and RC Trembath4 1 National Institute for
Health Research (NIHR) Biomedical Research Centre, Guy’s and St. Thomas’ NHS
Foundation Trust and King’s College London, London, United Kingdom, 2 Division of Genetics
and Molecular Medicine, King’s College London School of Medicine, London, United
Kingdom, 3 St John’s Institute of Dermatology, King’s College London, London, United
Kingdom and 4 Barts and the London School of Medicine and Dentistry, Queen Mary
University of London, London, United Kingdom
Many genetic loci have now been shown to influence psoriasis and these implicate a number of
genes providing evidence for an integrated model for the pathogenesis of psoriasis that combines
skin barrier function, innate immune pathogen sensing, adaptive immunity and Th17 cell responses.
There is one major disease susceptibility locus located within the major histocompatibility com-
plex (MHC), in which the signal is thought to be driven by HLA-C. Other independent association
loci have been identified within the MHC, but determining the number and location of these has
been hampered by extensive linkage disequilibrium across the region. We leveraged the power of
large discovery and replication datasets of European ancestry to look for further association signals
in the MHC region. In addition to the major loci at HLA-C (p=2.20 x10-236), we found and repli-
cated four additional hits, three of which are novel. The results from the discovery sample are as
follows; rs2507971 p= 6.73 x10-14, rs9260313 p=7.93 x10-09, rs66609536 p=3.54 x10-07 and
rs380924 p=6.24 x10-06), all replicate in an independent sample (p<=0.01). All lie within the MHC
Class I region. The previously identified loci lies near MICA, the other three lie near MICB, HLA-A
and HCG9 (a non-coding RNA). The identification of disease associations with both MICA and MICB
is particularly intriguing, since each encodes an MHC Class I-related protein with potent immuno-
logical function.
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Archeosomes as new therapy delivery vehicles for skin cells
M Liovic,1 M Ozir,1 A Ota,2 T Zupancic3 and N Poklar Ulrih2 1 Medical Centre for Molecular
Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 2 Biotechnical
Faculty, University of Ljubljana, Ljubljana, Slovenia and 3 National Institute of Chemistry,
Ljubljana, Slovenia
Archeosomes are a type of lipid bilayer vesicles (liposomes) that are made from extracted archaeal
lipids. These have unique structural characteristics that increase the lipid bilayer’s stability even
under high temperatures, low or high pH, presence of phospholipases and bile salts. Consequently
this has led to the development of new potential drug, gene and vaccine delivery systems. Here we
present the data obtained on large unilamellar archeosomes (400 nm size) extracted from Aeropy-
rum pernix K1, as a potential new method for drug/therapy delivery to skin cells. The core lipid of
A. pernix consists solely of C25,25-archaeol(2,3-di-sesterpanyl-sn-glycerol).C25-25archaetidyl(glu-
cosyl)inositol (AGI), with its glucosylinositol polar head-group accounts for 91 mol%, while C25,25-
archaetidylinositol (AI) with its myoinositol polar head-group, accounts for 9 mol%. The potential
cytotoxic effect of archeosomes on skin cells was measured using an in vitro cell metabolic activ-
ity assay. HaCaT keratinocytes grown in culture proved unaffected by archeosomes, even when
higher concentrations were used (500 μg/ml). Subsequently, large (400 nm in size) unilamellar
archeosomes were prepared, which were packed with calcein as reporter dye. Calcein is a fluo-
rescent dye that can be readily detected by spectrophotometer or under an epifluorescent micro-
scope. Archeosomes containing calcein were simply supplemented to keratinocyte growth medium
and cells were incubated for 24hrs. After 24hrs cells were fixed and examined under the micro-
scope. Our results show that in a confluent keratinocyte monolayer a large number of cells (30-
40%) displayed diffuse fluorescence due to arheosome intake and calcein release. Currently dif-
ferent types of archeosomes are being evaluated as possible new tools for drug or DNA/protein
delivery in a variety of cell culture in vitro model systems.
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Unexpected extradermatological findings in 31 Xeroderma Pigmentosum type C patients
S Hadj-Rabia,1 D Oriot,2 N Soufir,3 H Dufresne,1 A Taieb,4 A Sarasin5 and C Bodemer1 1 Service
de dermatologie, MAGEC, INSERM U781, Hôpital Necker - Enfants Malades, Université Paris
Descartes, Paris, France, 2 Pediatrics, Hôpital University Hospital of Poitiers, Poitiers, France,
3 Laboratoire de biochimie hormonale et génétique, Hôpital Xavier Bichat-Claude Bernard,
Paris, France, 4 Unité de dermatologie, CHU de Bordeaux Hôpital Pellegrin enfants,
Bordeaux, France and 5 Département de biopathologie, Institut de cancérologie Gustave
Roussy, Villejuif, France
Background: Xeroderma Pigmentosum type C is a rare autosomal recessive condition character-
ized by the association of various clinical manifestations mostly involving skin and eye. Objectives:
to evaluate the clinical manifestations in a homogeneous genetically characterized cohort of XP-C
patients. Methods: All patients with genetically or Unscheduled DNA Synthesis confirmed XP-C
from the registry of both our department and the french association of patients were contacted.
During a planned consultation, clinical information was collected using a standardized Case Record
Form. Results: 31 patients were seen. The mean age at diagnosis was 2.95 years; the onset of skin
symptoms occurred at 1.49 years. Among them, 51.72% had relative short stature with a height-
for-weight z-score less than -1 SD; 59.25% showed a pyramidal syndrome; and 45.16% had pho-
tophobia and/or conjunctivitis. Four patients had several pyogenic granulomas. Twenty-four patients
(77.4%) had skin cancer. The mean age of the onset of the first skin cancer was 4.76 years (range
2-14.5). Basal Cell Carcinoma was the most frequent cancer. Melanomas were rare and mostly
desmoplastic. Multinodular thyroid was the most frequent internal tumor. Conclusions: Our data
highlights several new aspects of XP-C. XPC patients are at risk to develop pyogenic granulomas,
desmoplastic melanomas and multinodular thyroid. Involvement of CNS is frequent but its mech-
anism remains unclear. The relative short stature needs further investigation to be explained. XP-C
is not only a cancer-prone disorder but also also a polysystemic disorder.
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Dystrophic epidermolysis bullosa with aplasia cutis congenita: genotype-phenotype correla-
tions
A Fernadez,1 C Chiaverini,1 A Charlesworth,1 M Youssef,1 JF Cuny,3 S Hadj Rabia,4 P Vabres,5
J Miquel J,6 JP Lacour2 and G Meneguzzi2 1 Reference Centre for Inherited Epidermolysis
Bullosa, Hospital Archet-2, Nice, France, 2 INSERM U1081-CNRS UMR 7284, Nice Sophia
Antipolis University, Nice, France, 3 Dermatology, Fournier Hospital, Nancy, France, 4
Dermatology, Necker Hospital, Paris, France, 5 Dermatology, Bocage Hospital, Dijon, France
and 6 Dermatology, CHU, Rennes, France
Occurrence of aplasia cutis congenita (ACC) is reported in all forms of inherited epidermolisis bul-
losa (EB), including dominant and recessive dystrophic EB (DDEB and RDEB). Because only a few
patients with DEB-ACC have been genotyped, we investigated possible genotype-phenotype cor-
relations in DEB-ACC. Among 16 DEB-ACC patients, six females and ten males, eleven presented
mild DEB (DDEB, RDEB-mitis and I-RDEB) while five suffered from severe RDEB-HS. ACC was bilat-
eral in 10 patients and involved feet in all cases, ankles in five, and legs and hands in four and one
cases, respectively. Atrophy of the affected limb was found in three patients. All patients displayed
enhanced skin fragility in atrophic scars of ACC. Direct sequencing of genomic DNA identified 24
COL7A1 mutations, of which 11 are novel. Patients with RDEB-HS were either homozygous for
nonsense mutations or compound heterozygous for a nonsense mutations and a splice site muta-
tion or a glycine substitution. Eleven patients with mild RDEB carried either a glycine (8 cases) or
an arginine substitution (one case), which are either associated with a mutation causing a prema-
ture termination codon (PTC) (3 patients), or a splice site mutation or another glycine substitution
(3 patients). One patient presented two glycine substitutions. Together with the information avail-
able in the literature, our data link DEB-ACC to glycine or arginine substitutions at specific posi-
tions in collagenic domains of the collagenVII polypeptide, which permits to hypothesize a nega-
tive effect on the stability of thermo-labile collagen VII molecules, which results in ACC in areas of
the body undergoing in utero traumatisms.
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Development of lentiviral gene therapy for type VII collagen deficient epidermolysis bullosa
C Georgiadis,1 A Thrasher,1 AP South,2 J McGrath,3 W Qasim1 and W Di1 1 Molecular
Immunology and Immunobiology, Institute of Child Health, UCL, London, United Kingdom, 2
Surgery and Molecular Oncology, University of Dundee, Dundee, United Kingdom and 3 St.
John’s Institute of Dermatology, KCL, London, United Kingdom
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe debilitating genodermatosis char-
acterised by severe blistering of the skin, chronic morbidity and predisposition to malignancy. This
autosomal recessive disorder is caused by mutations in the type VII collagen gene (COL7A1), result-
ing in loss of expression of COL7A1 protein essential for the anchoring of the epidermis to the der-
mis. To date, developed cell based therapies have included intradermal allogeneic fibroblast injec-
tions and allogeneic bone marrow stem cell therapy. We have been investigating ex-vivo correction
of autologous cells for the treatment of RDEB. A third generation lentiviral vector platform for the
delivery of an optimised COL7A1 transgene has been designed and constructed. Human COL7A1
deficient keratinocytes and fibroblasts with compound heterozygote mutations were transduced and
the reconstitution of COL7A1 expression was evaluated. The restoration of full length 290kda COL7A1
protein was confirmed by western blot analysis and was detected in both cell lysate and culture
medium. The expression was further supported by immuno-cytofluorescence staining. Durability of
COL7A1 expression was tracked for one month in transdcued cells and results showed stable expres-
sion. In addition, three dimensional organotypic cultures generated using transduced RDEB ker-
atinocytes and fibroblasts revealed restoration of COL7A1 protein at the dermal epidermal junction.
Genetically corrected cells were also grafted into a human/murine skin graft model and the results
will be confirmed shortly. Furthermore, functional restoration of COL7A1 assessed by wound sim-
ulation scratch assay was carried out and results showed migration rates decrease to normal levels
following the lentiviral transduction of COL7A1 deficient cells. All this suggests that gene therapy
using lentiviral corrected autologous cells is a feasible therapeutic approach for RDEB.
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Exome sequencing in sixteen familial cases of Hidradenitis Suppurativa supports locus het-
erogeneity and a role for genes independent of the γ-secretase complex
AE Pink,1 MA Simpson,1 N Desai,2 CH Smith,2 P Mortimer,3 RC Trembath1 and JN Barker1 1 King’s
College London, London, United Kingdom, 2 St. George’s University of London, London,
United Kingdom and 3 St. John’s Institute of Dermatology, London, United Kingdom
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that segregates as an auto-
somal dominant trait in some kindreds. Heterozygous mutations in the γ-secretase genes NCSTN,
PSENEN and PSEN1 have been reported to underlie a minority of familial and sporadic cases. The
aim of this study was to identify further causative genes. We undertook exome sequencing in 16
affected individuals (mutations and whole exon/gene deletions or duplications in NCSTN, PSEN1
or PSENEN previously excluded) from 14 multiplex kindreds using the Agilent Sure Select Target
Enrichment system and an Illumina HiSeq 2000. No novel variants were detected in NCSTN, PSE-
NEN or PSEN1, confirming our previous exclusion of these genes in this cohort. Furthermore, no
novel variants were detected in the remaining γ-secretase genes, PSEN2, APH1A or APH1B. No
rare variants (estimated population frequency <0.05) in the γ-secretase genes were found to exceed
their expected population frequencies. To investigate the potential role of genes outside of the γ-
secretase complex exome profiles were compared using an autosomal dominant model. Only novel
protein altering variants were considered as candidate pathogenic mutations. Each individual had
an average of 251 (136-570) such variants. A maximum of five individuals shared novel variation
in any one gene. These data support significant further locus heterogeneity in HS and imply the
involvement of genes independent of the γ-secretase complex. Exome sequencing has proved a
powerful tool in the investigation of rare Mendelian disorders however the application of this tech-
nique to clinically and genetically heterogeneous conditions such as HS is more challenging. Metic-
ulous phenotypic dissection and hypothesis driven bioinformatic analysis has the potential to high-
light further disease causing genes and thus the key molecular pathways underlying this debilitating
condition.
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Seven novel families with ADCL confirm clinical and molecular homogeneity
S Hadj-Rabia,1 B Callewaert,2 M Kempers,3 E Bourrat,4 M Renard,2 O Vanakker,2 F Malfait,2
PJ Coucke,2 A de Paepe2 and C Bodemer1 1 Service de dermatologie, MAGEC, INSERM U781,
Hôpital Necker - Enfants Malades, Université Paris Descartes, Paris, France, 2 Center for
Medical Genetics, Ghent University Hospital, Ghent, Belgium, 3 University Medical Center St.
Radboud, Nijmegen, Netherlands and 4 Service de dermatologie,, Hopital Saint-Louis, Paris,
France
Introduction and objectives: Elastin gene aberrations have been associated with a variety of phe-
notypes. Grossly, loss-of-function mutations result in arterial stenoses, while mutant protein expres-
sion induces cutis laxa. Autosomal dominant cutis laxa is a rare disorder that further presents with
typical facial characteristics, inguinal hernias, aortic root dilatation and pulmonary emphysema. In
most patients, frameshift mutations are found in the 3’ region of the elastin gene (exons 30-34) and
result in a C-terminally extended protein, but exceptions have been reported. Material and meth-
ods: This study presents a comprehensive clinical and molecular analysis of 7 families with ADCL.
Exons 28-34 of the ELN gene was sequenced at gDNA level. Results and conclusions: We report
21 patients from 7 families with ADCL, the largest cohort thus far reported, and found C-terminal
frameshift mutations in the elastin gene in all probands. Our data favor homogeneity both on the
clinical and molecular level. All mutations reside in exons 30, 32, 33 and 34. One mutational hotspot
in exon 32 (c.2262delA) is documented. We confirm the previously reported findings comprising
generalized skin involvement, inguinal hernia, aortic root dilatation and emphysema, necessitating
regular cardiovascular and pulmonary evaluations. We further evidence wide intra- and interfamilial
variability and amelioration of the skin phenotype in ageing patients. The two first and the two last
authors contributed equally to this work
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Long-term follow-up of patients with Herlitz type junctional epidermolysis bullosa
W Yuen,1 JC Duipmans,1 B Molenbuur,2 I Herpertz,3 JM Mandema4 and MF Jonkman1 1
Dermatology, University Medical Center Groningen, Groningen, Netherlands, 2
Anesthesiology, University Medical Center Groningen, Groningen, Netherlands, 3 Dietetics,
University Medical Center Groningen, Groningen, Netherlands and 4 Pediatrics, University
Medical Center Groningen, Groningen, Netherlands
Junctional epidermolysis bullosa, type Herlitz (JEB-H) is a rare, autosomal recessive disease caused
by a total absence of the epidermal basement membrane adhesion protein laminin-332. It is char-
acterized by extensive and devastating blistering of the skin and mucous membranes, leading to
death in early childhood. We present the long-term follow-up of the largest cohort of JEB-H patients
and we give guidelines for prognosis, treatment and care. In total, 22 JEB-H patients were included
in the Dutch Epidermolysis Bullosa Registry between 1988 and 2011 and they were followed lon-
gitudinally by our EB team. All patients deceased before they reached the age of three years, at an
average age of 5.8 months (range 0.5-32.6 months). The causes of death were, in order of fre-
quency, failure to thrive, respiratory failure, pneumonia, dehydration, anemia, sepsis, and euthana-
sia. The pattern of initial weight gain was the only predictor of lifespan that we could identify. Inva-
sive treatments to extend life did not promote survival in our patients. It is important to diagnose
JEB-H as soon as possible after birth, so that the management can be shifted from life saving to
comfort care. The palliative end-of-life care can take place in hospital, but is also safe in the home
setting. Suffering in JEB-H patients can become so unbearable, that in some patients, who do not
respond to adequate analgesic and sedative treatment, newborn euthanasia, performed according
to the Groningen protocol, is legally permitted in the Netherlands.
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Effects of an extract of Arctium lappa on gene expression of macrophages and dermal fibrob-
lasts under oxidative stress
E Pomari and B Stefanon Department of Agriculture and Environmental Sciences, University of
Udine, Udine, Italy
Although the biological activities of Arctium lappa (burdock) have been already investigated in
human and other species, no data evaluating the molecular mechanisms in skin have been reported.
We analysed the cytotoxicity of the extract of burdock on murine macrophages (RAW 264.7) and
canine dermal fibroblasts (DFs) at 24h. Then, we studied the activity of the extract (10μg/ml): 1) on
mRNA expression of specific inflammatory genes like Nuclear factor NFkappaB1 (Nfkb1), Nuclear
factor NFkappaB2 (Nfkb2), Interleukin 1β (Il1β), Tumor necrosis factorα (Tnfα), Interferonγ (Ifnγ),
Nitric oxide synthase inducible (Nos2) and Prostaglandin-endoperoxide synthase2 (COX2) in H2O2
(200μM for 1h) pretreated RAW 264.7 with qRT-PCR at 3 and 24h, and 2) on molecular response
in DFs with or w/o a H2O2 (200μM for 1h) prestimulation using RNAseq technology at 24h. The
extract showed a low cytotoxicity in RAW 264.7 and DFs also at high concentration (from 1 to
200μg/ml) in serum free medium. Nfkb1, Nfkb2, Ifnγ, Nos2 were down-regulated at 3h while Tnfα,
Il1β and COX2 did not show a decrease. The mRNA expression of all genes was depressed after
24h of incubation. The expression profile of DFs showed a significant upregulation of mitochondr-
ial Superoxide dismutase (SOD2) by burdock. H2O2 upregulated Glycogen synthase kinase 3β
(GSK3β) and downregulated Frizzled (FZD7) and Dishevelled (DVL3), while burdock upregulated
DVL3 and did not affect the expression of both GSK3β and FZD7. The modulation of these target
genes was validated by qRT-PCR. In addition, burdock showed a stimulation of chondroitin sulfate
biosynthesis by the upregulation of Glucuronylgalactosylproteoglycan 4-beta-N-acetylgalac-
tosaminyltransferasi. All the data suggest that A.lappa may be an effective remedy against skin dis-
orders with antinflammatory, antioxidative and regenerative effects, including the stimulation of
βcatenin through the modulation of DVL3 in the Wnt/βcatenin signaling with potential implication
for the wound healing process.
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A “Late-but-Fitter Revertant Cell” Explains the High Frequency of Revertant Mosaicism in Epi-
dermolysis Bullosa
PC van den Akker,1 AM Pasmooij,2 H Joenje,3 RM Hofstra,1 GJ te Meerman1 and MF Jonkman2 1
Genetics, University of Groningen, University Medical Center Groningen, Groningen,
Netherlands, 2 Dermatology, University of Groningen, University Medical Center Groningen,
Groningen, Netherlands and 3 Clinical Genetics and the Cancer Center Amsterdam/VUmc
Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, Netherlands
Revertant mosaicism is the phenomenon in which germline mutations are corrected by postzygotic
events. Revertant mosaicism was first reported in the heritable blistering disorder epidermolysis bul-
losa (EB) in 1997 by us. Although considered rare at first, revertant skin patches have been observed
in an increasing number of EB patients since, including all Dutch patients with generalized non-
Herlitz junctional EB. Revertant mosaicism might therefore be present in all EB patients with strongly
reduced protein expression in mutant skin. To gain further support for this hypothesis, we have used
a mathematical approach to estimate the probability that revertant patches due to single nucleotide
corrections occur in the skin of patients with recessive EB subtypes. Our developmental model pre-
dicts that reverse mutations are present in the skin of all these patients. However, reverse mutations
should arise during early embryogenesis to be able to produce clinically recognizable patches at
adult age. As the probability for reverse mutations to occur during early embryogenesis is low, a
clinically recognizable revertant patch could be expected only once in ~10,000 patients. This dis-
crepancy with our clinical observations cannot be explained by the various limitations to our
developmental model, like ignorance of cell loss and hierarchy among basal keratinocytes. We there-
fore hypothesize that reverse mutations provide revertant cells with a selective growth advantage
in situ, allowing them to result in clinically recognizable patches even if they occur during later
stages of development. Our “late-but-fitter revertant cell” hypothesis is supported by observations
in other genetic diseases and the centrifugal expansion of revertant patches into adjacent Blaschko-
line segments.
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Only Four Genes (EDA1, EDAR, EDARADD, and WNT10A) Account for 90% of Hypo-
hidrotic/Anhidrotic Ectodermal Dysplasia Cases
C Cluzeau,1 S Hadj-Rabia,2 M Jambou,3 C Bodemer2 and A Smahi1 1 INSERM U781, Hôpital
Necker - Enfants Malades, Université Paris Descartes, Paris, France, 2 Service de dermatolo-
gie, MAGEC, INSERM U781, Hôpital Necker - Enfants Malades, Université Paris Descartes,
Paris, France and 3 Laboratoire de Génétique, Hôpital Necker - Enfants Malades, Université
Paris Descartes, Paris, France
Introduction: Hypohidrotic and anhidrotic ectodermal dysplasia (HED/EDA) is a rare genodermatosis
characterized by abnormal development of sweat glands, teeth, and hair. Three disease-causing
genes have been hitherto identified, namely, (1) EDA1 accounting for X-linked forms, (2) EDAR,
and (3) EDARADD, causing both autosomal dominant and recessive forms. Recently, WNT10A gene
was identified as responsible for various autosomal recessive forms of ectodermal dysplasias, includ-
ing onycho-odontodermal dysplasia (OODD) and Schopf-Schulz-Passarge syndrome. Methods:
We systematically studied EDA1, EDAR, EDARADD, and WNT10A genes in a large cohort of 65
unrelated patients, of which 61 presented with HED/EDA. Results and conclusions: A total of 50
mutations (including 32 novel mutations) accounted for 60/65 cases in our series. These four genes
accounted for 92% (56/61 patients) of HED/EDA cases: (1) the EDA1 gene was the most common
disease-causing gene (58% of cases), (2)WNT10A and EDAR were each responsible for 16% of
cases. Moreover, a novel disease locus for dominant HED/EDA mapped to chromosome 14q12–q13.1.
Although no clinical differences between patients carrying EDA1, EDAR, or EDARADD mutations
could be identified, patients harboring WNT10A mutations displayed distinctive clinical features
(marked dental phenotype, no facial dysmorphism), helping to decide which gene should be first
investigated in HED/EDA.
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ABCC6 mutations in the Japanese patients with pseudoxanthoma elasticum
A Iwanaga Dermatology, Nagasaki University Graduate School of Biomedical Sciences,
Nagasaki, Japan
Pseudoxanthoma elasticum (PXE, OMIM; #264800) is an autosomal recessive disorder character-
ized by the aggregation, fragmentation, and calcium deposition of elastic fibers. It primarily affects
organs and tissues that are rich in elastic fibers, such as the skin and mucous, eye and blood ves-
sels. Patients with PXE are at an increased risk of visual loss or cardiovascular disease. The respon-
sible gene for PXE is ABCC6, which encodes MRP6, a transmembrane transporter protein. Although
hundreds of Caucasian PXE patients had been analyzed, there was no correlation between the muta-
tion pattern and the clinical phenotype of PXE. We have started mutation analysis of ABCC6 gene
in the Japanese PXE patients. Here, we present the result of the ABCC6 gene mutations. Data was
collected from 141 PXE patients (mean age = 58.1, 42 males, 99 females) from all over the coun-
try. In the 129 patients with skin symptoms, there are 88 cases with, 6 cases without angioid streaks,
and 35 cases have not been examined. In the 100 patients with angioid streaks, there are 88 cases
with, 9 cases without skin symptoms, and 3 cases have not been examined. Pathological examina-
tions revealed that calcification and degeneration of elastic fibers in 120 cases out of 141 patients.
We have completed DNA sequence of ABCC6 in 48 alleles of the 24 cases until now. We identi-
fied homozygous mutations in 9 cases, and compound heterozygous mutations in 6 cases, a single
heterozygous mutation in 8 cases, and no mutations in 2 cases. We identified nonsense mutations
in 10 alleles, missense mutations in 20 alleles, deletion in 4 alleles, and insertion in 6 alleles. The
most frequent mutation was nonsense mutation Q378X found in 9 alleles, which was also known
as a frequent mutation of ABCC6 in previous studies. The mutations were found in exon 2, 3, 8, 9,
10, 19, 24, 25, and 29. So far, there seems to be no correlation between mutations and severity in
Japanese PXE patients.
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Production of pluripotent stem and organ cells from skin biopsies of a patient with type II
diabetes and neonatal fibroblasts and examination of the cellular and molecular processes in
comparison to the corresponding parental cells
AM Hossini,1 A Prigione,2 B Lichtner,2 E Makrantonaki,1 J Adjaye2 and CC Zouboulis1 1
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical
Center, Dessau, Germany, Dessau, Germany and 2 Department of Vertebrate Genomics, Max
Planck Institute for Molecular Genetics, Berlin, Germany, Berlin, Germany
Human induced pluripotent stem (iPS) cells have enormous potential in terms of studying molecu-
lar pathogenesis of diseases and their use in regenerative medicine. Before the latter can be real-
ized, there are a number of questions to clear up. We have previously managed to generate iPS cells,
employing retroviruses which express the four transcriptional factors OCT4, SOX2, KLF4 and C-
MYC, from skin-derived fibroblasts obtained from a healthy neonate (BJ, HFF1, purchased from
ATCC) and from an 84 year-old patient suffering from type II diabetes (NFH-2). However, little is
known about the nature and sequence of molecular events accompanying nuclear reprogramming.
The aim of the project is to produce systemic organ cells from iPS cells in vitro as a model to inves-
tigate the molecular pathogenesis of systemic diseases and molecular processes in iPS cells. In order
to address the molecular cell processes of the generated iPS cells, we analysed among others the
parental somatic cells and their corresponding iPS cells with regard to chromosomal integrity and
formation of reactive oxygen species (ROS) and we found chromosomal abnormality in iPS cells
from the 84 year-old patient in contrast to iPS cells from neonatal fibroblasts. Both parental cells
showed chromosomal normality. Finally we differentiated the iPS cells into neuronal cells despite
chromosomal abnormality. In summary, we succeeded in producing systemic organ cells from iPS
cells in vitro, despited the detected chromosomal abnormalities.
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Cutaneous Gene Therapy Approach For The Correction Of Congenital Generalized Lipodys-
trophy
R Moro, B Duarte, R Murillas and F Larcher Epithelial biomedicine, CIEMAT, Madrid, Spain
Congenital generalized lipodystrophy is a rare autosomal recessive disorder characterized by marked
lack of body fat. Patients develop insulin resistance complications such as diabetes, dyslipidemia,
hepatic steatosis, acanthosis nigricans, polycystic ovarian disease and hypertension. These compli-
cations are derived from low serum levels of leptin and adiponectin, chemokines produced and
secreted by subcutaneous and visceral fat, in lipodystrofic patients. Mutations in 1-AcylGlycerol-
3-Phosphate O-AcylTransferase 2 (AGPAT2) gene lead to lipodystrophy by inhibiting triacylglycerol
synthesis and storage, and therefore causing absence of functional, chemokine-secreting adipocytes.
We are developing cellular and gene therapy protocols to achieve functional adipocytic differenti-
ation of dermal fibroblasts from lipodystrophic patients. For this purpose we have constructed viral
vectors to recover AGPAT2 activity in cultured fibroblasts and to subsequently differentiate them
into adipocytes by expression of Peroxisome Proliferator-Activated Receptor gamma (PPARg), a mas-
ter regulator of adipogenesis. Transduced cells, grown in specific culture conditions, efficiently dif-
ferentiate to adipocytes, that will be subsequently used in cellular therapy approaches to treat this
disease. We are currently analyzing patient-derived in vitro-differentiated adipocytes to assess their
ability to produce and secrete adipokines with the goal of using them to correct lipodystrophic
pathologies.
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Establishment and characterization of keratinocyte cell lines derived from RDEB patients to
assess cell and gene therapies in vitro and in vivo
C Chamorro,1 D Almarza,1 S Llames,2 R Murillas,1 J Cigudosa,3 M Escamez,1 A Mencia,1 R Garcia-
Escudero,1 M Del Rio1 and F Larcher1 1 CIEMAT, CIBERER, Madrid, Spain, 2 CCST, Oviedo,
Spain and 3 CNIO, Madrid, Spain
Recessive dystrophic Epidermolysis Bullosa (RDEB) is a skin fragility disease characterized by gen-
eralized skin blistering, mitten deformities and cancer proneness. The RDEB sev-gen form is char-
acterized by type VII collagen absence due to COL7A1 mutations among which the recurrent
c.6527insC is found in the Spanish population. Recently, several experimental therapeutic strate-
gies, to be further tested, emerged as potential modalities to treat RDEB. Skin humanized mouse
models of genodermatoses including EB appear as robust systems to test enduring cell/gene thera-
pies. However, feasibility assessment of currently inefficient approaches such as homologous recom-
bination requires the analysis of large numbers of cell clones, a difficult assignment even for highly
clonogenic human keratinocytes. Thus, cell lines with enhanced proliferative and clonogenic capac-
ities as compared to parental primary cells but capable to reproduce the disease phenotype in vivo
would be highly valuable. Using either the SV40 large T antigen or E6-E7 proteins from papillo-
mavirus (HPV16) we immortalized keratinocytes from two RDEB sev-gen patients carrying the
c.6527insC pathogenic mutation. Clones derived from each parental cell line exhibited high pro-
liferative and colony forming features. Cytogenetic analysis revealed that large T antigen-driven
immortalization induced higher karyotype abnormalities than those achieved by E6-E7 immortal-
ization. When tested in vivo for organotypic behaviour upon grafting to immunodeficient mice, both
cell lines were capable to regenerate an epidermis without dysplastic or neoplastic signs. Prelimi-
nary studies showed that both cell lines faithfully recapitulated the EB blistering phenotype in vivo.
These RDEB cell lines represent useful tools to test novel therapeutic approaches currently under
investigation including those aimed at COL7A1 gene editing.
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Expression of miRNAs in cutaneous squamous cell cancer
B Burger,1 C Bruegger,1 J De Mesmaeker,1 W Kempf2 and PH Itin3 1 Department of Biomedicine,
University Hospital Basel, Basel, Switzerland, 2 Kempf and Pfaltz Histological Diagnostics,
University Hospital Zurich, Zurich, Switzerland and 3 Department of Dermatology, University
Hospital Basel, Basel, Switzerland
Cutaneous squamous cell cancer (cSCC) is one of the most common skin cancers, accounting for
about 16% of skin cancers; 1% of all cSCC lead to death. Numerous pathways are reported to be
involved in the development of cSCCs, including EGFR, Ras, NF-κB, and TNFα. MicroRNAs (miRNA)
are strongly conserved small RNAs (about 21-22 nucleotides in average), which regulate transla-
tion of more than 1/3 of all human mRNAs. Usually, they bind to the 3’-UTR of the mRNA leading
to degradation or inhibition of translation of target mRNA. Up to now more than 1000 human miR-
NAs are known. Involvement of miRNAs in cSCC development is rarely analysed and knowledge
about relation of miRNAs and cSCC development is insufficiently. Our approach is to look for expres-
sion analyses of such miRNAs in cSCC which are known to be involved in development of cuta-
neous and non-cutaneous SCC types. We isolated total mRNA from formalin-fixed and paraffin-
embedded (FFPE) well-differentiated cSCCs of individuals without cancer predisposition as well as
from epidermis of patients without SCC as control. TaqMan-assay for quantification of specific miR-
NAs were performed for 12 several miRNAs, which were previously reported to be involved in sev-
eral types of cancer. Expression analyses showed four differentially expressed miRNAs (miR-21,
miR-31, miR-155, and miR-205), which were all upregulated in cSCCs; none of examined miRNAs
were detectably downregulated by the used method. miRNA-21 was previously described to be
upregulated in cutaneous SCCs, whereas miRNA-205 was not regulated in that study. The other miR-
NAs (miR-31 and miR-155) were never reported in context with cSCCs, but are known to be upreg-
ulated in non-cutaneous SCC. miRNAs are known to be important players in carcinogenesis. Our
experiments reveal that hitherto existing data present diverse results. To achieve reliable data fur-
ther analyses have to be performed in consideration of the cSCC differentiation.
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Technical loss of heterozygosity (TLOH) in mutation analysis by a SNP located in the primer
binding site in two cases of epidermolysis bullosa (eb)
A Klausegger,1 K Cox,2 N Grasern,1 F Wacha,1 DF Murrell3 and JW Bauer1 1 Department of
Dermatology, Division of Molecular Dermatology and EB House Austria, Salzburg, Austria, 2
Department of Pathology, Women’s and Children’s Hospital, North Adelaide, SA, Australia
and 3 Department of Dermatology, St George Hospital, Sydney, NSW, Australia
Database analysis of genes involved in eb reveals a small percentage of non-detectable mutations
due to PCR contaminations with extrinsic DNA, large deletions erasing the region for primer bind-
ing, genomic re-arrangements and not yet defined molecular mechanisms. Here we describe the
loss of one heterozygous mutation during the process of mutation analysis in two different cases of
recessive inherited eb. In a family with junctional eb type Herlitz we analyzed the LAMA3 gene.
The paternal deletion of 1644delG in exon14 was detected in the first cycle of screening, while the
maternal mutation of 4465G>T (G1489X) in exon 33, detected during the second run of the screen,
was missing. This had a dramatically impact on prenatal diagnosis for the family as it was impossi-
ble to give an exact prognosis for the genotype of the fetus that resulted in a sibling with Herlitz
type of eb. In the second family with eb simplex we screened the gene PLEC1 for inherited muta-
tions. The paternal mutation of 6955C>T (R2319X) in exon 31 was detected as heterozygous stop
mutation, whereas the maternal mutation was a homozygous duplication of 331-332 dupTC in exon
3 suggesting a partial isodisomy. Analysis of this exon with a new primer set showed a heterozy-
gous duplication, indicating the loss of the wildtype allele by PCR amplification with the initially
used primer set. The detection of only one mutation or the occurrence of an untypical combination
of homozygous and heterozygous mutations should lead to generate a new PCR primer set with
alternative binding sites within the introns to exclude TLOH. Using the alternative primer set the
putative not detected second mutation appeared clearly in the sequence of PCR. Therefore in spe-
cial cases we recommend the usage of a second alternative primer set to improve the sensitivity of
mutation analysis.
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Late onset pretibial recessive dystrophic epidermolysis bullosa
A Mahto,1 M Rustin1 and J McGrath2 1 Department of Dermatology, Royal Free Hospital,
London, United Kingdom and 2 Department of Dermatology, Guys and St Thomas’ Hospital,
London, United Kingdom
A 62-year old male gave a 10 year history of an intermittently itchy red rash on both shins with occa-
sional blistering and abnormal toenails. He was otherwise well with no significant family history.
On examination the patient had bilateral, well-defined, slightly indurated, erythematous plaques
affecting the pretibial area with evidence of resolving bullae. There were similar areas affecting the
medial aspect of the calf. His toenails were globally dystrophic. Skin biopsy showed a large, cell-
poor sub-epidermal bulla. The roof was intact and fibrin was present at the base. The underlying
dermis contained a mild chronic inflammatory cell infiltrate comprising lymphocytes and histio-
cytes but no neutrophils or eosinophils. Direct immunofluorescence and porphyria screen was
negative. Genetic testing was carried out to screen for mutations in the COL7A1 gene. This identi-
fied our patient was a compound heterozygote for two pathogenic mutations: a frameshift muta-
tion in exon 31 (c.3840delC; p.Gly1281ValfsX44) and a missense mutation in exon 113 (c.8371C>T;
p.Arg2791Trp). These findings establish a diagnosis of recessive dystrophic epidermolysis bullosa;
clinically this was of the pretibial subtype. Pretibial epidermolysis bullosa (PEB) is a rare form of
localised dystrophic epidermolysis bullosa and is characterised by recurrent blistering and hyper-
trophic scarring occurring predominantly in the pretibial area with nail dystrophy. Disease occurs
due to loss of dermal-epidermal adhesion and altered anchoring fibrils following mutations in the
type VII collagen gene (COL7A1). Diagnosis is often delayed due to late age of onset and intrafa-
milial variability. Our patient’s missense mutation (Arg2971Tryp) in exon 113 has previously been
reported in two patients. However, in both cases, patients suffered with features of generalised
DEB. Our patient is unusual due to his mild clinical phenotype. This case highlights a rare variant
of disease and stresses the importance of molecular diagnosis.
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Methylenetetrahydrofolate reductase C677T and A1298C mutations and chronic idiopathic
acrocyanosis
F Sampogna, DB Camaioni, AR Giampetruzzi, R Corona, L Ruzzi, L Silvestri and B Didona
Istituto Dermopatico dell’Immacolata (IDI)-IRCCS, Rome, Italy
The purpose of the study was to investigate the presence of two methylenetetrahydrofolate reduc-
tase (MTHFR) polymorphisms, C677T and A1298C, in patients with chronic idiopathic acrocyanosis,
and to compare their prevalence to a control group. The case-control study was conducted on 43
consecutive patients with acrocyanosis and on 100 controls. Genomic DNA was isolated and ampli-
fied using the polymerase chain reaction. Odds ratios (OR) and 95% confidence intervals (95% CI)
were used to estimate the risk of developing chronic idiopathic acrocyanosis according to the
genotypes. The risk of acrocyanosis was significantly higher in patients homozygous for the muta-
tion C677T compared to those with no mutation, with an OR of 4.8 (95%CI 1.5-14.9). In cases, the
prevalence of the C mutation of the A1298C polymorphism was lower than in the control group.
The homozygosity for the C677T polymorphism was associated with an increased homocysteine
level. On the basis of our findings, acrocyanosis could be considered as a cutaneous sign of a “latent”
cardiovascular risk. This should be taken into account particularly when acrocyanosis is associated
either to other medical conditions that determine a vessel wall damage, or to conditions that pre-
dispose to the risk of thromboembolism.
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Regulating the expression of genes associated with the protection and maintenance of skin
structure via topical treatment
R Gopaul, DG Kern, HE Knaggs and JF Lephart Nu Skin Enterprises, Provo, UT
Nu Skin Center for Anti-aging Research, Nu Skin Enterprise, Provo, Utah USA One of the most
noticeable signs of skin aging is the loss of skin structure resulting in a sagging, wrinkled appear-
ance. Within the last decade, there have been hundreds of studies done on ingredients that address
this attribute of skin aging. This study investigates the in-vitro effect of a blend of Narcisscus Tazetta
Bulb Extract and Schizandra Chinensis Fruit Extract on genes related to skin structure integrity. Nar-
cisscus Tazetta Bulb Extract and Schizandra Chinensis Fruit Extract are well-known for their health
benefits when taken orally. However, limited research has been done on the benefits of topical appli-
cations of these extracts. Recent unpublished in-house studies of a combination of these two extracts
have led to the hypothesis that when combined Narcisscus Tazetta Bulb Extract and Schizandra
Chinensis Fruit may be able to protect and maintain the structure of the skin, helping to prevent the
appearance of aged skin. A combination of Narcissus Tazetta Bulb Extract and Schizandra Chinen-
sis Fruit Extract was applied to human equivalent skin cultures containing normal human epider-
mal keratinocytes and fibroblasts. RNA extracted after 24 hours of culture incubation from both
treated and untreated culture samples were used to conduct RT-PCR experiments. Results showed
that when combined, Narcisscus Tazetta Bulb Extract and Schizandra Chinensis Fruit induced the
expression of genes associated with the protection and maintenance of skin structure while reduc-
ing the expression of genes known to degrade skin structure. The genes that were upregulated include,
LOX, PKP2, RBP2, SOD2, TGM1, TIMP1, FOX03 and COL4A3. The genes that were downregu-
lated include, ERBB2 and HRH1. Based on the results from this study, it can be concluded that when
combined Narcisscus Tazetta Bulb Extract and Schizandra Chinensis Fruit may be able to protect
and maintain the integrity and structure of skin resulting in younger skin appearance.
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R-Equol and/or Racemic Equol Demonstrate Better Expression of Skin-Related Genes Com-
pared to S-Equol: In Vitro Evidence with Clinical Implications
E Lephart Physiology/Neuroscience, Brigham Young University, Provo, UT
Equol is a polyphenolic molecule similar in chemical structure to other plant-derived compounds
like resveratrol. Equol is an isoflavonoid derived from intestinal metabolism and dietary plant and
other food sources. Equol has the unique characteristics to bind specifically 5alpha-dihydrotestos-
terone (to decrease this negative impact in skin), has affinity for estrogen receptor beta (to increase
positive influences on skin) and can be found as R-equol and S-equol. The purpose of this study: to
show the differential expression of skin-related genes where the positive effects of equol is due to
R-equol and/or Racemic equol and not S-equol. The methods utilized were EpiDermal Thickness
(EFT) human skin equivalents to test R-equol vs. racemic equol vs. S-equol at 1.2 % compared to
dimethyl sulfoxide controls (24 hr. exposure) for gene/mRNA expression for many skin-related mol-
ecules. Approximately one-half of the 40 genes tested displayed significant changes in the bio-
markers. Only 3 of the skin-related genes displayed the greatest expression by S-equol, whereas,
16 of the genes displayed the greatest levels by R-equol and/or Racemic equol for the quantified
biomarkers. The summarized results include: collagen, elastin and TIMP 1 were significantly increased
by R-equol and/or Racemic equol compared to S-equol. MMP 1, MMP 3 and MMP 9 were signif-
icantly decreased by R-equol and/or Racemic compared to S-equol. For anti-oxidant, aging and
inflammatory gene biomarkers a similar results was observed where R-equol and/or Racemic equol
compared to S-equol displayed more positive results [for example: for nerve growth factor, FOS,
S100 calcium-binding proteins (A8 & A9), steroid 5alpha-reductase type 1, interleukin 1, interleukin
6 and cyclooxygenase 1]. Conclusions, these data demonstrate that: 1) R-equol and/or Racemic
equol are better molecules for skin gene biomarker outcomes compared to S-equol and 2) R-equol
and/or Racemice equol would be more potent and effective active ingredients in skin and hair appli-
cations compared to S-equol.
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Genetic investigations on a Hungarian family with Brooke-Spiegler Syndrome
N Nagy,1 N Rajan,3 K Farkas,2 ÁGNES Kinyó,1 L Kemény1 and M Széll2 1 Department of
Dermatology and Allergology, University of Szeged, Szeged, Hungary, 2 Dermatological
Research Group of the Hungarian Academy of Sciences, University of Szeged, Szeged,
Hungary and 3 Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne,
United Kingdom
Brooke-Spiegler symdrome (BSS; OMIM 605041) is an autosomal dominant condition character-
ized by the development of skin appendage tumors, such as cylindromas, trichoepitheliomas and
spiradenomas. BSS develops due to mutations in the tumour suppressor gene, CYLD. We investi-
gated a Hungarian BSS pedigree with Bukovinian (Romanian) origin containing 21 affected family
members spanning 7 generations. Direct sequencing of the coding regions of the CYLD gene revealed
a nonsense mutation (c.2806C>T, p.Arg936X) in exon 20 of the CYLD gene. Since this nonsense
mutation is present in an Anglo-Saxon pedigree from the north of England, we are planning to per-
form the haplotype analysis of the two geographically distant pedigrees to reveal whether the muta-
tion they carry is the result of two independent mutational events or they are carrying the same
founding mutation.
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A case report on the combination of Neurofibromatosis type 1 and Klippel-Trenaunay Syn-
drome
K Farkas,1 N Nagy,2 G Szolnoky,2 L Kemény2 and M Széll1 1 Dermatological Research Group of
the Hungarian Academy of Sciences, University of Szeged, Szeged, Hungary and 2
Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
Neurofibromatosis type 1 (NF1; OMIM 162200), an autosomal dominant condition characterized
by the development of cafe-au-lait spots, axillary freckling, Lisch nodules, cutaneous fibromatous
tumors, scoliosis and increased susceptibility to malignant tumors, is the consequence of mutations
in the neurofibromin gene (NF1). Klippel-Trenaunay Syndrome (KTS; OMIM 149000) is featured by
angio-osteohypertrophy localized typically unilaterally on lower extremity. The genetic background
of KTS has not yet been fully elucidated. Recently we have identified a 52-year-old Hungarian
woman presenting the clinical phenotypes of both NF1 and KTS. We aimed to identify the under-
lying genetic abnormality of this interesting case. Direct sequencing of the coding regions and the
flanking introns of the NF1 gene revealed a novel frameshift mutation (c.5727insT, p.V1909fsX1912)
in exon 39. The patient carried the mutation in a heterozygous form, while the unrelated controls
carried only the wild type sequence. Further studies are needed to unreveal whether the newly iden-
tified mutation is responsible for the development of both the phenotypes of NF1 and KTS or there
is a second yet unidentified mutation responsible for the angio-osteohypertrophy of the right leg of
the patient.
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Absence of filaggrin mutation in Pachyonychia Congenita-6a and atopic dermatitis
G Pertusi,1 E Giardina,2 A Terrinoni,2 R Cascella,2 V Serra,2 C Bornacina,3 R Tiberio,3 G Novelli,4
G Melino2 and E Colombo3 1 S.Andrea Hospital, Vercelli, Italy, 2 Tor Vergata University of
Rome, Roma, Italy, 3 University of Piemonte Orientale “A. Avogadro”, Novara, Italy and 4
National Agency for evaluation of Universities and Research, Roma, Italy
Pachyonychia Congenita (PC) is a rare autosomal-dominant inherited keratin disorders character-
ized by onychodystrophy and other associated ectodermal features. Since in PC there can be dif-
ferences in phenotype severity between mutation in the same genes and between patients carrying
the same mutation, environmental or genetic modifiers were suggested. In particular, PC shares
some clinical features with atopic dermatitis, a common inflammatory skin disorder associated with
epidermal barrier dysfunction and filaggrin (FLG) mutation and it has been recently reported that
filaggrin gene mutations could influence phenotype severity of PC. We investigated some genetic,
immunologic and clinical features in a 3- month-old girl of Morocco origin, our proband, affected
with a severe form of PC and mild atopic dermatitis. Genomic DNA was extracted from peripheral
blood of our proband, her parents and her brother, using standard procedures to detect keratin and
filaggrin gene mutations. At clinical examination, we observed thickening of fingernails and toe-
nails bed with progressive distal elevation associated to subungueal hyperkeratosis, leukokeratosis
of the tongue and left plantar blister, pathognomonic features of PC but also follicular hyperkeratosis
associated to cutaneous xerosis and repeated cases of perioral impetigo, minor signs of atopic der-
matitis. Since mutation analysis, revealed the presence of a deletion in exon 1 of K6a gene only in
our proband, which removed asparagine (p.Asn172del) we performed the diagnosis of sporadic case
of PC-6a. Sequencing of FLG gene on our patient blood sample did not reveal any mutations. The
absence of FLG mutation in our patient suggest that other environmental and genetic modifier should
be investigate to explain the different clinical phenotypes of PC.
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